Jazz Pharmaceuticals (JAZZ) 10-Q 2 Nov 20 2020 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2020	Oct. 27, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-33500
Entity Registrant Name	Jazz Pharmaceuticals plc
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1032470
Entity Address, Address Line One	Fifth Floor, Waterloo Exchange,
Entity Address, Address Line Two	Waterloo Road
Entity Address, City or Town	Dublin 4
Entity Address, Country	IE
Entity Address, Postal Zip Code	D04 E5W7
Country Region	353
City Area Code	1
Local Phone Number	634-7800
Title of 12(b) Security	Ordinary shares, nominal value $0.0001 per share
Trading Symbol	JAZZ
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		55,714,006
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal period Focus	Q3
Entity Central Index Key	0001232524
Current Fiscal Year End Date	--12-31

CONDENSENED CONSOLIDATED BALANC

CONDENSENED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 741,942	$ 637,344
Investments	1,175,000	440,000
Accounts receivable, net of allowances	361,664	355,987
Inventories	91,404	78,608
Prepaid expenses	58,305	39,434
Other current assets	127,258	78,895
Total current assets	2,555,573	1,630,268
Property, plant and equipment, net	128,204	131,506
Operating lease assets	130,717	139,385
Intangible assets, net	2,241,107	2,440,977
Goodwill	937,099	920,018
Deferred tax assets, net	254,810	221,403
Deferred financing costs	5,802	7,426
Other non-current assets	38,646	47,914
Total assets	6,291,958	5,538,897
Current liabilities:
Accounts payable	67,063	45,732
Accrued liabilities	302,071	269,686
Current portion of long-term debt	243,999	33,387
Income taxes payable	25,910	10,965
Deferred revenue	3,090	4,720
Total current liabilities	642,133	364,490
Deferred revenue, non-current	2,951	4,861
Long-term debt, less current portion	1,843,685	1,573,870
Operating lease liabilities, less current portion	141,925	151,226
Deferred tax liabilities, net	141,588	224,095
Other non-current liabilities	142,475	109,374
Commitments and contingencies (Note 11)
Shareholders’ equity:
Ordinary shares	6	6
Non-voting euro deferred shares	55	55
Capital redemption reserve	472	472
Additional paid-in capital	2,537,989	2,266,026
Accumulated other comprehensive loss	(187,801)	(223,393)
Retained earnings	1,026,480	1,067,815
Total shareholders’ equity	3,377,201	3,110,981
Total liabilities and shareholders’ equity	$ 6,291,958	$ 5,538,897

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenues	$ 600,888	$ 537,702	$ 1,698,050	$ 1,580,021
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)	42,095	31,400	98,760	92,582
Selling, general and administrative	207,255	178,706	607,061	522,667
Research and development	78,647	79,855	243,676	202,344
Intangible asset amortization	66,684	62,863	192,505	181,324
Acquired in-process research and development	10,000	51,775	215,250	109,975
Impairment charge	0	0	136,139	0
Total operating expenses	404,681	404,599	1,493,391	1,108,892
Income from operations	196,207	133,103	204,659	471,129
Interest expense, net	(27,428)	(17,861)	(72,134)	(54,017)
Foreign exchange loss	(639)	(1,033)	(2,235)	(3,577)
Income before income tax provision (benefit) and equity in loss of investees	168,140	114,209	130,290	413,535
Income tax provision (benefit)	19,283	10,903	22,750	(38,631)
Equity in loss of investees	623	1,030	2,338	2,791
Net income	$ 148,234	$ 102,276	$ 105,202	$ 449,375
Net income per ordinary share:
Basic (in dollars per share)	$ 2.67	$ 1.80	$ 1.89	$ 7.90
Diluted (in dollars per share)	$ 2.64	$ 1.78	$ 1.87	$ 7.80
Weighted-average ordinary shares used in per share calculations - basic (in shares)	55,545	56,674	55,637	56,860
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	56,236	57,438	56,297	57,647
Product sales, net
Revenues:
Total revenues	$ 596,949	$ 532,321	$ 1,685,357	$ 1,559,075
Royalties and contract revenues
Revenues:
Total revenues	$ 3,939	$ 5,381	$ 12,693	$ 20,946

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 148,234	$ 102,276	$ 105,202	$ 449,375
Other comprehensive income (loss):
Foreign currency translation adjustments	47,139	(48,448)	37,879	(56,271)
Unrealized gain (loss) on hedging activities, net of income tax provision (benefit) of $167, ($80), ($327) and ($769), respectively	1,169	(558)	(2,287)	(5,380)
Other comprehensive income (loss)	48,308	(49,006)	35,592	(61,651)
Total comprehensive income	$ 196,542	$ 53,270	$ 140,794	$ 387,724

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) effect on hedging activities	$ 167	$ (80)	$ (327)	$ (769)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Ordinary Shares	Non-voting Euro Deferred	Capital Redemption Reserve	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, AdjustmentRetained Earnings
Beginning balance (in shares) at Dec. 31, 2018		57,504	4,000
Beginning balance at Dec. 31, 2018	$ 2,757,422	$ 6	$ 55	$ 472	$ 2,113,630	$ (197,791)	$ 841,050	$ 4,848	$ 4,848
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of ordinary shares in conjunction with exercise of share options (in shares)		54
Issuance of ordinary shares in conjunction with exercise of share options	3,057				3,057
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)		203
Shares withheld for payment of employee's withholding tax liability	(13,810)				(13,810)
Share-based compensation	27,861				27,861
Shares repurchased (in shares)		(858)
Shares repurchased	(111,249)						(111,249)
Other comprehensive loss	(22,883)					(22,883)
Net (loss) income	85,201						85,201
Ending balance (in shares) at Mar. 31, 2019		56,903	4,000
Ending balance at Mar. 31, 2019	2,730,447	$ 6	$ 55	472	2,130,738	(220,674)	819,850
Beginning balance (in shares) at Dec. 31, 2018		57,504	4,000
Beginning balance at Dec. 31, 2018	2,757,422	$ 6	$ 55	472	2,113,630	(197,791)	841,050	$ 4,848	$ 4,848
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Other comprehensive loss	(61,651)
Net (loss) income	449,375
Ending balance (in shares) at Sep. 30, 2019		56,619	4,000
Ending balance at Sep. 30, 2019	3,054,405	$ 6	$ 55	472	2,209,156	(259,442)	1,104,158
Beginning balance (in shares) at Mar. 31, 2019		56,903	4,000
Beginning balance at Mar. 31, 2019	2,730,447	$ 6	$ 55	472	2,130,738	(220,674)	819,850
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of ordinary shares in conjunction with exercise of share options (in shares)		98
Issuance of ordinary shares in conjunction with exercise of share options	7,033				7,033
Issuance of ordinary shares under employee stock purchase plan (in shares)		57
Issuance of ordinary shares under employee stock purchase plan	6,032				6,032
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)		15
Shares withheld for payment of employee's withholding tax liability	(1,003)				(1,003)
Share-based compensation	28,658				28,658
Shares repurchased (in shares)		(447)
Shares repurchased	(59,869)						(59,869)
Other comprehensive loss	10,238					10,238
Net (loss) income	261,898						261,898
Ending balance (in shares) at Jun. 30, 2019		56,626	4,000
Ending balance at Jun. 30, 2019	2,983,434	$ 6	$ 55	472	2,171,458	(210,436)	1,021,879
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of ordinary shares in conjunction with exercise of share options (in shares)		110
Issuance of ordinary shares in conjunction with exercise of share options	9,968				9,968
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)		32
Shares withheld for payment of employee's withholding tax liability	(1,087)				(1,087)
Share-based compensation	28,817				28,817
Shares repurchased (in shares)		(149)
Shares repurchased	(19,997)						(19,997)
Other comprehensive loss	(49,006)					(49,006)
Net (loss) income	102,276						102,276
Ending balance (in shares) at Sep. 30, 2019		56,619	4,000
Ending balance at Sep. 30, 2019	3,054,405	$ 6	$ 55	472	2,209,156	(259,442)	1,104,158
Beginning balance (in shares) at Dec. 31, 2019		56,140	4,000
Beginning balance at Dec. 31, 2019	3,110,981	$ 6	$ 55	472	2,266,026	(223,393)	1,067,815
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of ordinary shares in conjunction with exercise of share options (in shares)		145
Issuance of ordinary shares in conjunction with exercise of share options	13,264				13,264
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)		214
Shares withheld for payment of employee's withholding tax liability	(13,547)				(13,547)
Share-based compensation	28,731				28,731
Shares repurchased (in shares)		(1,131)
Shares repurchased	(139,053)						(139,053)
Other comprehensive loss	(34,043)					(34,043)
Net (loss) income	(157,833)						(157,833)
Ending balance (in shares) at Mar. 31, 2020		55,368	4,000
Ending balance at Mar. 31, 2020	2,808,500	$ 6	$ 55	472	2,294,474	(257,436)	770,929
Beginning balance (in shares) at Dec. 31, 2019		56,140	4,000
Beginning balance at Dec. 31, 2019	3,110,981	$ 6	$ 55	472	2,266,026	(223,393)	1,067,815
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Other comprehensive loss	35,592
Net (loss) income	105,202
Ending balance (in shares) at Sep. 30, 2020		55,592	4,000
Ending balance at Sep. 30, 2020	3,377,201	$ 6	$ 55	472	2,537,989	(187,801)	1,026,480
Beginning balance (in shares) at Mar. 31, 2020		55,368	4,000
Beginning balance at Mar. 31, 2020	2,808,500	$ 6	$ 55	472	2,294,474	(257,436)	770,929
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of Exchangeable Senior Notes, due 2026	176,260				176,260
Partial repurchase of Exchangeable Senior Notes, due 2021	(12,069)				(12,069)
Issuance of ordinary shares in conjunction with exercise of share options (in shares)		74
Issuance of ordinary shares in conjunction with exercise of share options	4,440				4,440
Issuance of ordinary shares under employee stock purchase plan (in shares)		65
Issuance of ordinary shares under employee stock purchase plan	6,547				6,547
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)		19
Shares withheld for payment of employee's withholding tax liability	(1,116)				(1,116)
Share-based compensation	30,599				30,599
Shares repurchased (in shares)		(70)
Shares repurchased	(7,484)						(7,484)
Other comprehensive loss	21,327					21,327
Net (loss) income	114,801						114,801
Ending balance (in shares) at Jun. 30, 2020		55,456	4,000
Ending balance at Jun. 30, 2020	3,141,805	$ 6	$ 55	472	2,499,135	(236,109)	878,246
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Partial repurchase of Exchangeable Senior Notes, due 2021	(444)				(444)
Issuance of ordinary shares in conjunction with exercise of share options (in shares)		96
Issuance of ordinary shares in conjunction with exercise of share options	10,088				10,088
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)		40
Shares withheld for payment of employee's withholding tax liability	(1,097)				(1,097)
Share-based compensation	30,307				30,307
Other comprehensive loss	48,308					48,308
Net (loss) income	148,234						148,234
Ending balance (in shares) at Sep. 30, 2020		55,592	4,000
Ending balance at Sep. 30, 2020	$ 3,377,201	$ 6	$ 55	$ 472	$ 2,537,989	$ (187,801)	$ 1,026,480

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities
Net income	$ 105,202	$ 449,375
Adjustments to reconcile net income to net cash provided by operating activities:
Intangible asset amortization	192,505	181,324
Share-based compensation	89,614	84,626
Impairment charge	136,139	0
Depreciation	14,076	10,885
Acquired in-process research and development	215,250	109,975
Deferred tax benefit	(120,909)	(167,935)
Provision for losses on accounts receivable and inventory	9,148	3,847
Loss on extinguishment of debt	5,089	0
Amortization of debt discount and deferred financing costs	40,613	34,415
Other non-cash transactions	12,672	(1,638)
Changes in assets and liabilities:
Accounts receivable	(5,004)	(4,307)
Inventories	(21,861)	(23,028)
Prepaid expenses and other current assets	(64,902)	(22,858)
Other non-current assets	13,941	(540)
Operating lease assets	9,730	10,919
Accounts payable	20,645	29,104
Accrued liabilities	26,510	(37,369)
Income taxes payable	15,089	42,813
Deferred revenue	(3,540)	(4,234)
Other non-current liabilities	33,254	(3,634)
Operating lease liabilities, less current portion	(9,884)	(3,137)
Net cash provided by operating activities	713,377	688,603
Investing activities
Proceeds from maturity of investments	920,000	820,000
Purchases of property, plant and equipment	(10,889)	(32,998)
Acquisitions, net of cash acquired	0	(55,074)
Acquired in-process research and development	(215,250)	(61,700)
Acquisition of intangible assets	(113,000)	(80,500)
Acquisition of investments	(1,661,750)	(585,975)
Net cash provided by (used in) investing activities	(1,080,889)	3,753
Financing activities
Net proceeds from issuance of Exchangeable Senior Notes, due 2026	981,381	0
Proceeds from revolving credit facility	500,000	0
Proceeds from employee equity incentive and purchase plans	34,339	26,090
Payment of employee withholding taxes related to share-based awards	(15,760)	(15,900)
Repayments of long-term debt	(25,040)	(25,040)
Share repurchases	(146,537)	(191,115)
Payments for partial repurchase of Exchangeable Senior Notes, due 2021	(356,188)	0
Repayments under revolving credit facility	(500,000)	0
Net cash provided by (used in) financing activities	472,195	(205,965)
Effect of exchange rates on cash and cash equivalents	(85)	(838)
Net increase in cash and cash equivalents	104,598	485,553
Cash and cash equivalents, at beginning of period	637,344	309,622
Cash and cash equivalents, at end of period	$ 741,942	$ 795,175

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
The Company and Summary of Significant Accounting Policies	The Company and Summary of Significant Accounting Policies Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases – often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Our lead marketed products are: • Xyrem ® (sodium oxybate) oral solution , a product approved by the U.S. Food and Drug Administration, or FDA, and marketed in the U.S. for the treatment of both cataplexy and excessive daytime sleepiness, or EDS, in narcolepsy patients seven years of age and older; • Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution , a product that contains 92% less sodium than Xyrem, approved by FDA and launched in the U.S. in November 2020 for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; • Sunosi ® (solriamfetol) , a product approved by FDA and marketed in the U.S. and in Europe to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea; • Defitelio ® (defibrotide sodium) , a product approved in the U.S. for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, or VOD, also known as sinusoidal obstruction syndrome, with renal or pulmonary dysfunction following hematopoietic stem cell transplantation, or HSCT, and in Europe (where it is marketed as Defitelio ® (defibrotide)) for the treatment of severe VOD in adults and children undergoing HSCT therapy; • Erwinaze ® (asparaginase Erwinia chrysanthemi ) , a treatment approved in the U.S. and in certain markets in Europe (where it is marketed as Erwinase ® ) for patients with acute lymphoblastic leukemia, or ALL, who have developed hypersensitivity to E. coli -derived asparaginase; • Vyxeos ® (daunorubicin and cytarabine) liposome for injection , a product approved in the U.S. and in Europe (where it is marketed as Vyxeos ® liposomal 44 mg/100 mg powder for concentrate for solution for infusion) for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia, or AML, or AML with myelodysplasia-related changes; and • Zepzelca ™ (lurbinectedin) , a product approved by FDA in June 2020 and launched in July 2020 in the U.S. for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy. Throughout this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “the registrant,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. Throughout this report, all references to “ordinary shares” refer to Jazz Pharmaceuticals plc’s ordinary shares. Basis of Presentation These unaudited condensed consolidated financial statements have been prepared following the requirements of the U.S. Securities and Exchange Commission for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or U.S. GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10‑Q should be read in conjunction with our annual consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020, for any other interim period or for any future period. Our significant accounting policies have not changed substantially from those previously described in our Annual Report on Form 10-K for the year ended December 31, 2019. These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries, and intercompany transactions and balances have been eliminated. Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the identification, development and commercialization of meaningful pharmaceutical products that address unmet medical needs. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Adoption of New Accounting Standards In August 2018, the Financial Accounting Standards Board, or FASB, issued ASU No. 2018-15, “Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. We adopted this standard on January 1, 2020 and adoption did not have a material impact on our consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” which simplifies the accounting for goodwill impairment by eliminating Step 2 of the goodwill impairment test. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. We adopted this standard on January 1, 2020 and adoption did not have a material impact on our consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. We adopted this standard on January 1, 2020 and adoption did not have a material impact on our consolidated financial statements. In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (ASC 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” which contains optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform. ASC 848 allows for different elections to be made at different points in time, and the timing of those elections will be documented as applicable. For the avoidance of doubt, we intend to reassess the elections of optional expedients and exceptions included within ASC 848 related to our hedging activities and will document the election of these items on a quarterly basis. ASC 848 is effective for us as of January 1, 2020 and will no longer be available to apply after December 31, 2022. In June 2020, we elected the expedient in ASC 848-50-25-2, which allows us to assume that our hedged interest payments will probably occur regardless of any expected modification in their terms related to reference rate reform. Significant Risks and Uncertainties With the global impact of the COVID-19 pandemic, we have developed a comprehensive response strategy including establishing cross-functional response teams and implementing business continuity plans to manage the impact of the COVID-19 pandemic on our employees, patients and our business. Since the second quarter of 2020, we have been experiencing financial and other impacts of the pandemic, and given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, we expect that our business, financial condition, results of operations and growth prospects will continue to be adversely affected in future quarters. With respect to our commercialization activities, the evolving effects of the COVID-19 pandemic continue to have a negative impact on demand, new patient starts and treatments for our products, primarily due to the inherent limitations of telemedicine and a reprioritization of healthcare resources toward COVID-19. The extent of the impact on our ability to generate sales of and revenues from our approved products, execute on new product launches, our clinical development and regulatory efforts, our corporate development objectives and the value of and market for our ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration and severity of the pandemic, governmental “stay-at-home” orders and travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Ireland and other countries, and the effectiveness of actions taken globally to contain and treat the disease. Our financial results are significantly influenced by sales of Xyrem. Our future plans assume that our newly launched oxybate product Xywav, with 92% lower sodium compared to Xyrem, absence of a sodium warning and dosing titration option, will become the treatment of choice for patients who can benefit from oxybate treatment, current Xyrem patients, and patients who previously were not prescribed Xyrem, including those patients for whom sodium content is a concern. While we expect that our business will continue to be substantially dependent on oxybate product sales from both Xyrem and Xywav, there is no guarantee that we can maintain oxybate sales at or near historical levels, or that oxybate sales will continue to grow. Our ability to maintain or increase oxybate sales is subject to a number of risks and uncertainties including, without limitation, those related to the introduction of authorized generic and generic versions of sodium oxybate and/or new products for treatment of cataplexy and/or EDS in narcolepsy in the U.S. market, the current and potential impacts of the ongoing COVID-19 pandemic, including the current and expected future negative impact on demand for our products and the uncertainty with respect to our ability to meet commercial demand in the future, increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including our ability to obtain and maintain adequate coverage and reimbursement for Xywav, challenges to our intellectual property around Xyrem and Xywav, and continued acceptance of Xyrem by physicians and patients and acceptance of Xywav by payors, physicians and patients. In addition to risks related specifically to Xyrem and Xywav, we are subject to other challenges and risks related to successfully commercializing a portfolio of oncology products and other neuroscience products, including Sunosi, Defitelio, Erwinaze, Vyxeos and Zepzelca, and other risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of our late-stage product candidates; effectively commercializing our recently approved products such as Sunosi, Zepzelca and Xywav; obtaining and maintaining adequate coverage and reimbursement for our products; increasing scrutiny of pharmaceutical product pricing and resulting changes in healthcare laws and policy; market acceptance; delays or problems in the supply of our products, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations. In addition, to the extent the COVID-19 pandemic continues to adversely affect our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above. Concentrations of Risk Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet. We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of September 30, 2020, we had foreign exchange forward contracts with notional amounts totaling $300.5 million. As of September 30, 2020, the outstanding foreign exchange forward contracts had a net liability fair value of $0.1 million. As of September 30, 2020, we had interest rate swap contracts with notional amounts totaling $300.0 million. These outstanding interest rate swap contracts had a net liability fair value of $4.1 million as of September 30, 2020. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant. We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and as of September 30, 2020 and December 31, 2019, allowances on receivables were not material. As of September 30, 2020, two customers accounted for 81% of gross accounts receivable, Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for 73% of gross accounts receivable, and McKesson Corporation and affiliates, or McKesson, which accounted for 8% of gross accounts receivable. As of December 31, 2019, two customers accounted for 89% of gross accounts receivable, ESSDS, which accounted for 77% of gross accounts receivable, and McKesson, which accounted for 12% of gross accounts receivable. We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to Xyrem, the API is manufactured for us by a single source supplier and the finished product is manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based Xyrem supplier. Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes", which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December 15, 2020 with early adoption permitted. The new guidance is not expected to have a material impact on our results of operations and financial position. In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions that are required for contracts to qualify for equity classification and eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. This new standard will be effective for us for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than the fiscal year beginning after December 15, 2020. We may elect to apply the amendments on a retrospective or modified retrospective basis. We are currently evaluating the timing, method of adoption and overall impact of this standard on our consolidated financial statements.

License Agreement

License Agreement	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License Agreement	License Agreement On December 19, 2019, we entered into an exclusive license agreement, or original license agreement, with Pharma Mar, S.A., or PharmaMar, for development and U.S. commercialization of Zepzelca. Zepzelca was granted orphan drug designation for relapsed SCLC by FDA in August 2018. In December 2019, PharmaMar submitted a new drug application, or NDA, to FDA for accelerated approval of Zepzelca for relapsed SCLC based on data from a Phase 2 trial, and in February 2020, FDA accepted the NDA for filing with priority review. In June 2020, FDA approved the NDA for Zepzelca for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy. Under the terms of the original license agreement, which became effective in January 2020 upon expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, we paid PharmaMar an upfront payment of $200.0 million, which was recorded as in-process research and development, or IPR&D expense in our condensed consolidated statements of income for the nine months ended September 30, 2020. In June 2020, we made a milestone payment of $100.0 million to PharmaMar following FDA accelerated approval of Zepzelca, which was capitalized as an intangible asset on our condensed consolidated balance sheet. PharmaMar is eligible to receive potential future regulatory milestone payments of up to $150.0 million upon the achievement of continued U.S. regulatory approval of Zepzelca following the successful completion of confirmatory trials within certain timelines. PharmaMar is also eligible to receive up to $550.0 million in potential U.S. commercial milestone payments, as well as incremental tiered royalties on future net sales of Zepzelca ranging from the high teens up to 30 percent. PharmaMar may receive additional payments on approval of other indications, with any such payments creditable against commercial milestone payment obligations. PharmaMar retains production rights for Zepzelca and will supply the product to us.

Cash and Available-for-Sale Sec

Cash and Available-for-Sale Securities	9 Months Ended
	Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Cash and Available-for-Sale Securities	Cash and Available-for-Sale Securities Cash, cash equivalents and investments consisted of the following (in thousands): September 30, 2020 Amortized Gross Gross Estimated Cash and Investments Cash $ 406,338 $ — $ — $ 406,338 $ 406,338 $ — Time deposits 1,255,000 — — 1,255,000 80,000 1,175,000 Money market funds 255,604 — — 255,604 255,604 — Totals $ 1,916,942 $ — $ — $ 1,916,942 $ 741,942 $ 1,175,000 December 31, 2019 Amortized Gross Gross Estimated Cash and Investments Cash $ 333,172 $ — $ — $ 333,172 $ 333,172 $ — Time deposits 460,000 — — 460,000 20,000 440,000 Money market funds 284,172 — — 284,172 284,172 — Totals $ 1,077,344 $ — $ — $ 1,077,344 $ 637,344 $ 440,000 Cash equivalents and investments are considered available-for-sale securities. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the condensed consolidated statements of income. Our investment balances represent time deposits with original maturities of greater than three months and less than one year. Interest income from available-for-sale securities was $2.1 million and $9.7 million in the three and nine months ended September 30, 2020, respectively, and $5.4 million and $15.2 million in the three and nine months ended September 30, 2019, respectively.

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The following table summarizes, by major security type, our available-for-sale securities and derivative contracts as of September 30, 2020 and December 31, 2019 that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands): September 30, 2020 December 31, 2019 Quoted Significant Total Quoted Significant Total Assets: Available-for-sale securities: Time deposits $ — $ 1,255,000 $ 1,255,000 $ — $ 460,000 $ 460,000 Money market funds 255,604 — 255,604 284,172 — 284,172 Foreign exchange forward contracts — 4,079 4,079 — 2,508 2,508 Totals $ 255,604 $ 1,259,079 $ 1,514,683 $ 284,172 $ 462,508 $ 746,680 Liabilities: Interest rate contracts $ — $ 4,143 $ 4,143 $ — $ 1,515 $ 1,515 Foreign exchange forward contracts — 4,221 4,221 — 182 182 Totals $ — $ 8,364 $ 8,364 $ — $ 1,697 $ 1,697 As of September 30, 2020, our available-for-sale securities included time deposits and money market funds and their carrying values were approximately equal to their fair values. Time deposits were measured at fair value using Level 2 inputs and money market funds were measured using quoted prices in active markets, which represent Level 1 inputs. Level 2 inputs, obtained from various third party data providers, represent quoted prices for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived from or corroborated by other observable market data. Our derivative assets and liabilities include interest rate and foreign exchange derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the fair value hierarchy. There were no transfers between the different levels of the fair value hierarchy in 2020 or 2019. As of September 30, 2020, the carrying amount of investments measured using the measurement alternative for equity investments without a readily determinable fair value was $4.5 million. The carrying amount, which is recorded within other non-current assets, represents the purchase price paid in 2018.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities We are exposed to certain risks arising from operating internationally, including fluctuations in interest rates on our outstanding term loan borrowings and fluctuations in foreign exchange rates primarily related to the translation of euro-denominated net monetary liabilities, including intercompany balances, held by subsidiaries with a U.S. dollar functional currency. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. To achieve a desired mix of floating and fixed interest rates on our variable rate debt, we entered into interest rate swap agreements in March 2017 which are effective until July 2021. These agreements hedge contractual term loan interest rates. As of September 30, 2020 and December 31, 2019, the interest rate swap agreements had a notional amount of $300.0 million. As a result of these agreements, the interest rate on a portion of our term loan borrowings was fixed at 1.895%, plus the borrowing spread, until July 12, 2021. The effective portion of changes in the fair value of derivatives designated as, and that qualify as, cash flow hedges is recorded in accumulated other comprehensive loss and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. The impact on accumulated other comprehensive loss and earnings from derivative instruments that qualified as cash flow hedges for the three and nine months ended September 30, 2020 and 2019 was as follows (in thousands): Three Months Ended Nine Months Ended Interest Rate Contracts: 2020 2019 2020 2019 Gain (loss) recognized in accumulated other comprehensive loss, net of tax $ 9 $ (322) $ (4,515) $ (4,361) Loss (gain) reclassified from accumulated other comprehensive loss to interest expense, net of tax 1,160 (236) 2,228 (1,019) A ssuming no change in London Inter-Bank Offered Rate, or LIBOR, based interest rates from market rates as of September 30, 2020, $3.6 million of losses, net of tax, recognized in accumulated other comprehensive loss will be reclassified to earnings over the next 12 months. We enter into foreign exchange forward contracts, with durations of up to 12 months, designed to limit the exposure to fluctuations in foreign exchange rates related to the translation of certain non-U.S. dollar denominated liabilities, including intercompany balances. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of September 30, 2020 and December 31, 2019, the notional amount of foreign exchange contracts where hedge accounting is not applied was $300.5 million and $180.9 million, respectively. The foreign exchange loss in our condensed consolidated statements of income included the following gains and losses associated with foreign exchange contracts not designated as hedging instruments (in thousands): Three Months Ended Nine Months Ended Foreign Exchange Forward Contracts: 2020 2019 2020 2019 Gain (loss) recognized in foreign exchange loss $ 9,549 $ (7,430) $ 6,943 $ (10,718) The cash flow effects of our derivative contracts for the nine months ended September 30, 2020 and 2019 are included within net cash provided by operating activities in the condensed consolidated statements of cash flows. The following tables summarize the fair value of outstanding derivatives (in thousands): September 30, 2020 Asset Derivatives Liability Derivatives Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments: Interest rate contracts Other current assets $ — Accrued liabilities $ 4,143 Derivatives not designated as hedging instruments: Foreign exchange forward contracts Other current assets 4,079 Accrued liabilities 4,221 Total fair value of derivative instruments $ 4,079 $ 8,364 December 31, 2019 Asset Derivatives Liability Derivatives Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments: Interest rate contracts Other current assets $ — Accrued liabilities $ 855 Other non-current liabilities 660 Derivatives not designated as hedging instruments: Foreign exchange forward contracts Other current assets 2,508 Accrued liabilities 182 Total fair value of derivative instruments $ 2,508 $ 1,697 Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our interest rate contracts and foreign exchange forward contracts subject to such provisions (in thousands): September 30, 2020 Gross Amounts of Recognized Assets/ Liabilities Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Gross Amounts Not Offset in the Consolidated Balance Sheet Description Derivative Financial Instruments Cash Collateral Received (Pledged) Net Amount Derivative assets $ 4,079 $ — $ 4,079 $ (2,255) $ — $ 1,824 Derivative liabilities (8,364) — (8,364) 2,255 — (6,109) December 31, 2019 Gross Amounts of Recognized Assets/ Liabilities Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Gross Amounts Not Offset in the Consolidated Balance Sheet Description Derivative Financial Instruments Cash Collateral Received (Pledged) Net Amount Derivative assets $ 2,508 $ — $ 2,508 $ (596) $ — $ 1,912 Derivative liabilities (1,697) — (1,697) 596 — (1,101)

Inventories

Inventories	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following (in thousands): September 30, December 31, Raw materials $ 17,338 $ 13,595 Work in process 46,278 36,658 Finished goods 27,788 28,355 Total inventories $ 91,404 $ 78,608

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The gross carrying amount of goodwill was as follows (in thousands): Balance at December 31, 2019 $ 920,018 Foreign exchange 17,081 Balance at September 30, 2020 $ 937,099 The gross carrying amounts and net book values of our intangible assets were as follows (in thousands): September 30, 2020 December 31, 2019 Remaining Gross Accumulated Net Book Gross Accumulated Net Book Acquired developed technologies 12.7 $ 3,324,806 $ (1,083,699) $ 2,241,107 $ 3,166,485 $ (864,834) $ 2,301,651 Manufacturing contracts — 12,533 (12,533) — 12,025 (12,025) — Trademarks — 2,903 (2,903) — 2,890 (2,890) — Priority review voucher — — — — 111,101 (111,101) — Total finite-lived intangible assets 3,340,242 (1,099,135) 2,241,107 3,292,501 (990,850) 2,301,651 Acquired IPR&D assets — — — 139,326 — 139,326 Total intangible assets $ 3,340,242 $ (1,099,135) $ 2,241,107 $ 3,431,827 $ (990,850) $ 2,440,977 The decrease in the gross carrying amount of intangible assets as of September 30, 2020 compared to December 31, 2019 reflects the impairment of our acquired IPR&D assets of $136.1 million following the decision to stop enrollment in our Phase 3 clinical study of defibrotide for the prevention of VOD due to a determination that the study is highly unlikely to reach one of its primary endpoints and the redemption of our priority review voucher in January 2020, partially offset by the capitalization of milestone payments of $100.0 million and $13.0 million triggered by FDA approval of Zepzelca in June 2020 and European Marketing Authorization of Sunosi in January 2020, respectively, and the positive impact of foreign currency translation adjustments due to the strengthening of the euro against the U.S. dollar. The assumptions and estimates used to determine future cash flows and remaining useful lives of our intangible and other long-lived assets are complex and subjective. They can be affected by various factors, including external factors, such as industry and economic trends, and internal factors such as changes in our business strategy and our forecasts for specific product lines. Based on finite-lived intangible assets recorded as of September 30, 2020, and assuming the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands): Year Ending December 31, Estimated 2020 (remainder) $ 66,819 2021 219,309 2022 172,424 2023 172,424 2024 172,424 Thereafter 1,437,707 Total $ 2,241,107

Certain Balance Sheet Items

Certain Balance Sheet Items	9 Months Ended
	Sep. 30, 2020
Certain Balance Sheet Items [Abstract]
Certain Balance Sheet Items	Certain Balance Sheet Items Property, plant and equipment consisted of the following (in thousands): September 30, December 31, Leasehold improvements $ 53,670 $ 52,294 Land and buildings 47,385 47,053 Manufacturing equipment and machinery 32,077 28,860 Computer software 22,868 25,680 Computer equipment 17,850 16,577 Furniture and fixtures 11,447 11,152 Construction-in-progress 6,072 5,147 Subtotal 191,369 186,763 Less accumulated depreciation and amortization (63,165) (55,257) Property, plant and equipment, net $ 128,204 $ 131,506 Accrued liabilities consisted of the following (in thousands): September 30, December 31, Rebates and other sales deductions $ 113,062 $ 96,860 Employee compensation and benefits 76,890 80,531 Sales returns reserve 13,574 3,462 Current portion of operating lease liabilities 13,078 12,728 Royalties 10,186 6,931 Inventory-related accruals 9,318 7,816 Consulting and professional services 8,430 7,665 Derivative instrument liabilities 8,364 1,037 Accrued interest 7,762 7,540 Clinical trial accruals 7,614 3,141 Selling and marketing accruals 7,721 10,946 Accrued collaboration expenses 730 2,494 Accrued construction-in-progress 474 3,015 Other 24,868 25,520 Total accrued liabilities $ 302,071 $ 269,686

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	Debt The following table summarizes the carrying amount of our indebtedness (in thousands): September 30, December 31, 2021 Notes $ 218,812 $ 575,000 Unamortized discount and debt issuance costs on 2021 Notes (8,207) (38,865) 2021 Notes, net 210,605 536,135 2024 Notes 575,000 575,000 Unamortized discount and debt issuance costs on 2024 Notes (101,099) (117,859) 2024 Notes, net 473,901 457,141 2026 Notes 1,000,000 — Unamortized discount and debt issuance costs on 2026 Notes (186,595) — 2026 Notes, net 813,405 — Term loan 589,773 613,981 Total debt 2,087,684 1,607,257 Less current portion 243,999 33,387 Total long-term debt $ 1,843,685 $ 1,573,870 2026 Notes In the second quarter of 2020, Jazz Investments I Limited, our wholly owned subsidiary, completed a private placement of $1,000.0 million principal amount of the 2026 Notes. We used a portion of the net proceeds from this offering to repurchase for cash $332.9 million aggregate principal amount of the 2021 Notes through privately-negotiated transactions concurrently with the offering of the 2026 Notes. Interest on the 2026 Notes is payable semi-annually in cash in arrears on June 15 and December 15 of each year, beginning on December 15, 2020, at a rate of 2.00% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2026 Notes. The 2026 Notes mature on June 15, 2026, unless earlier exchanged, repurchased or redeemed. The holders of the 2026 Notes have the ability to require us to repurchase all or a portion of their 2026 Notes for cash in the event we undergo certain fundamental changes, such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq Capital Market (or any of their respective successors). Additionally, the terms and covenants in the indenture related to the 2026 Notes include certain events of default after which the 2026 Notes may be due and payable immediately. Prior to June 15, 2026, we may redeem the 2026 Notes, in whole but not in part, subject to compliance with certain conditions, if we have, or on the next interest payment date would, become obligated to pay to the holder of any 2026 Notes additional amounts as a result of certain tax-related events. We also may redeem the 2026 Notes on or after June 20, 2023 and prior to March 15, 2026, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide the notice of redemption. The 2026 Notes are exchangeable at an initial exchange rate of 6.4182 ordinary shares per $1,000 principal amount of 2026 Notes, which is equivalent to an initial exchange price of approximately $155.81 per ordinary share. Upon exchange, the 2026 Notes may be settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal amount of the 2026 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of the 2026 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of the 2026 Notes who elect to exchange their 2026 Notes in connection with that make-whole fundamental change or during the related redemption period. Prior to March 15, 2026, the 2026 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. In accounting for the issuance of the 2026 Notes, we separated the 2026 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the estimated fair value of a similar liability that does not have an associated exchange feature. The carrying amount of the equity component representing the exchange option was determined by deducting the fair value of the liability component from the face value of the 2026 Notes as a whole. The excess of the principal amount of the liability component over its carrying amount will be amortized to interest expense over the expected life of the 2026 Notes using the effective interest method with an effective interest rate of 5.98% per annum. We have determined the expected life of the 2026 Notes to be equal to the original 6-year term. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. We allocated the total issuance costs incurred of $18.6 million to the liability and equity components based on their relative values. Issuance costs attributable to the liability component will be amortized to expense over the term of the 2026 Notes, and issuance costs attributable to the equity component were included with the equity component in our shareholders’ equity. Concurrently with the offering of the 2026 Notes, we repurchased $332.9 million aggregate principal amount of the 2021 Notes. In the third quarter of 2020, we repurchased a further $23.3 million aggregate principal amount of the 2021 Notes. We recorded a loss on extinguishment of debt of $0.6 million and $5.1 million, in the three and nine months ended September 30, 2020, respectively, due to the write-off of unamortized debt issuance costs and debt discount related to the partial repurchase of the 2021 Notes. We accounted for the difference between the consideration transferred and the fair value of the liability component of the 2021 Notes that were repurchased, of $12.5 million, as a reduction to the equity component. As of September 30, 2020, the principal amount of the 2021 Notes remaining was $218.8 million. The Exchangeable Senior Notes were issued by Jazz Investments I Limited, or the Issuer, a 100%-owned finance subsidiary of Jazz Pharmaceuticals plc. The Exchangeable Senior Notes are senior unsecured obligations of the Issuer and are fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc. No subsidiary of Jazz Pharmaceuticals plc guaranteed the Exchangeable Senior Notes. Subject to certain local law restrictions on payment of dividends, among other things, and potential negative tax consequences, we are not aware of any significant restrictions on the ability of Jazz Pharmaceuticals plc to obtain funds from the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries by dividend or loan, or any legal or economic restrictions on the ability of the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries to transfer funds to Jazz Pharmaceuticals plc in the form of cash dividends, loans or advances. There is no assurance that in the future such restrictions will not be adopted. As of September 30, 2020, the carrying values of the equity component of the 2021 Notes, 2024 Notes and the 2026 Notes, net of equity issuance costs, were $114.4 million, $149.8 million and $176.3 million, respectively. Maturities Scheduled maturities with respect to our long-term debt principal balances outstanding as of September 30, 2020 were as follows (in thousands): Year Ending December 31, Scheduled Long-Term Debt Maturities 2020 (remainder) $ 8,347 2021 252,198 2022 33,387 2023 517,494 2024 575,000 Thereafter 1,000,000 Total $ 2,386,426

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases	Leases The components of the lease expense for the three and nine months ended September 30, 2020 and 2019 were as follows (in thousands): Three Months Ended Nine Months Ended Lease Cost 2020 2019 2020 2019 Operating lease cost $ 5,501 $ 5,746 $ 16,201 $ 17,672 Short-term lease cost 942 396 2,702 1,616 Variable lease cost 1 — 2 4 Sublease income — (158) (224) (478) Net lease cost $ 6,444 $ 5,984 $ 18,681 $ 18,814 Supplemental balance sheet information related to operating leases was as follows (in thousands): Leases Classification September 30, December 31, Assets Operating lease assets Operating lease assets $ 130,717 $ 139,385 Liabilities Current Operating lease liabilities Accrued liabilities 13,078 12,728 Non-current Operating lease liabilities Operating lease liabilities, less current portion 141,925 151,226 Total operating lease liabilities $ 155,003 $ 163,954 Lease Term and Discount Rate September 30, December 31, Weighted-average remaining lease term - operating leases (years) 9.1 9.7 Weighted-average discount rate - operating leases 5.3 % 5.3 % Supplemental cash flow information related to operating leases was as follows (in thousands): Nine Months Ended 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 16,915 $ 11,758 Non-cash operating activities: Right-of-use assets obtained in exchange for new operating lease liabilities (1) $ 1,034 $ 153,048 _____________________________ (1) The September 30, 2019 disclosure includes the balances recognized on January 1, 2019 on adoption of ASU No. 2016-02, Leases. Maturities of operating lease liabilities were as follows (in thousands): Year Ending December 31, Operating leases 2020 (remainder) $ 4,812 2021 21,618 2022 21,619 2023 21,778 2024 23,992 Thereafter 104,794 Total lease payments 198,613 Less imputed interest (43,610) Present value of lease liabilities $ 155,003

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Indemnification In the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations. We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognize any liabilities relating to these obligations as of September 30, 2020 and December 31, 2019. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations. Other Commitments As of September 30, 2020, we had $75.4 million of noncancelable purchase commitments due within one year, primarily related to agreements with third party manufacturers. Legal Proceedings On June 17, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by Blue Cross and Blue Shield Association, or BCBS, against Jazz Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland Limited, or, collectively, the Company Defendants (hereinafter referred to as the BCBS Lawsuit). The BCBS Lawsuit also names Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth (USA), Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceuticals, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., and Lupin Inc., or, collectively, the BCBS Defendants. On June 18 and June 23, 2020, respectively, two additional class action lawsuits were filed against the Company Defendants and the BCBS Defendants: one by the New York State Teamsters Council Health and Hospital Fund in the United States District Court for the Northern District of California, and another by the Government Employees Health Association Inc. in the United States District Court for the Northern District of Illinois (hereinafter referred to as the GEHA Lawsuit). On June 18, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of California by the City of Providence, Rhode Island, on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc, and Roxane Laboratories, Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals USA Inc., and Hikma Pharmaceuticals plc, or, collectively, the City of Providence Defendants. On June 30, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by UFCW Local 1500 Welfare Fund on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals Ireland Ltd., Jazz Pharmaceuticals, Inc., Roxane Laboratories, Inc., Hikma Pharmaceuticals plc, Eurohealth (USA), Inc. and West-Ward Pharmaceuticals Corp., or collectively the UFCW Defendants (hereinafter referred to as the UFCW Lawsuit). On July 13, 2020, the plaintiffs in the BCBS Lawsuit and the GEHA Lawsuit dismissed their complaints in the United States District Court for the Northern District of Illinois, and refiled their respective lawsuits in the United States District Court for the Northern District of California. On July 14, 2020, the plaintiffs in the UFCW Lawsuit dismissed their complaint in the United States District Court for the Northern District of Illinois and on July 15, 2020, refiled their lawsuit in the United States District Court for the Northern District of California. On July 31, 2020, a class action lawsuit was filed in the United States District Court for the Southern District of New York by the A.F. of L.-A.G.C Building Trades Welfare Plan on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc (hereinafter referred to as the AFL Plan Lawsuit). The AFL Plan Lawsuit also names Roxane Laboratories Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceuticals Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc. On August 14, 2020, an additional class action lawsuit was filed in the United States District Court for the Southern District of New York by the Self-Insured Schools of California on behalf of itself and all others similarly situated, against the Company Defendants, as well as Hikma Pharmaceuticals plc, Eurohealth (USA) Inc., Hikma Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Roxane Laboratories, Inc., Amneal Pharmaceuticals LLC, Endo International, plc, Endo Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Lupin Inc., Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Holdings USA, Inc., Sun Pharmaceutical Industries, Inc., Ranbaxy Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Watson Laboratories, Inc., Wockhardt Ltd., Morton Grove Pharmaceuticals, Inc., Wockhardt USA LLC, Mallinckrodt plc, and Mallinckrodt LLC (hereinafter the Self-Insured Schools Lawsuit). On September 16, 2020, an additional class action lawsuit was filed in the United States District Court for the Northern District of California, by Ruth Hollman on behalf of herself and all others similarly situated, against the same defendants named in the Self-Insured Schools Lawsuit. The plaintiffs in certain of the lawsuits are seeking to represent a class of direct purchasers of Xyrem, and the plaintiffs in the remaining lawsuits are seeking to represent a class of indirect purchasers of Xyrem. Each of the lawsuits generally alleges violations of U.S. federal and state antitrust, consumer protection, and unfair competition laws in connection with the Company Defendants’ conduct related to Xyrem, including actions leading up to, and entering into, patent litigation settlement agreements with each of the other named defendants. Each of the lawsuits seeks monetary damages, exemplary damages, equitable relief against the alleged unlawful conduct, including disgorgement of profits and restitution, and injunctive relief. It is possible that additional lawsuits will be filed against the Company Defendants making similar or related allegations. If the plaintiffs were to be successful in their claims, they may be entitled to injunctive relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. From time to time we are involved in legal proceedings arising in the ordinary course of business. We believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders’ Equity Share Repurchase Program In November 2016, our board of directors authorized a share repurchase program and as of September 30, 2020 had authorized the repurchase of ordinary shares having an aggregate purchase price of up to $1.5 billion, exclusive of any brokerage commissions. Under this program, which has no expiration date, we may repurchase ordinary shares from time to time on the open market. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the amended credit agreement, corporate and regulatory requirements and market conditions. The share repurchase program may be modified, suspended or discontinued at any time without prior notice. During the three months ended September 30, 2020, we did not repurchase any of our ordinary shares. In the nine months ended September 30, 2020, we spent a total of $146.5 million to purchase 1.2 million of our ordinary shares under the share repurchase program at an average total purchase price, including commissions, of $121.98 per share. All ordinary shares repurchased were canceled. As of September 30, 2020, the remaining amount authorized under the share repurchase program was $431.2 million. Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss as of September 30, 2020 and December 31, 2019 were as follows (in thousands): Net Unrealized Foreign Total Balance at December 31, 2019 $ (1,325) $ (222,068) $ (223,393) Other comprehensive income (loss) before reclassifications (4,515) 37,879 33,364 Amounts reclassified from accumulated other comprehensive loss 2,228 — 2,228 Other comprehensive income (loss), net (2,287) 37,879 35,592 Balance at September 30, 2020 $ (3,612) $ (184,189) $ (187,801) During the nine months ended September 30, 2020, other comprehensive income reflects foreign currency translation adjustments, primarily due to the strengthening of the euro against the U.S. dollar, and the net unrealized loss on derivatives that qualify as cash flow hedges.

Net Income per Ordinary Share

Net Income per Ordinary Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Income per Ordinary Share	Net Income per Ordinary Share Basic net income per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding. Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Numerator: Net income $ 148,234 $ 102,276 $ 105,202 $ 449,375 Denominator: Weighted-average ordinary shares used in per share calculations - basic 55,545 56,674 55,637 56,860 Dilutive effect of employee equity incentive and purchase plans 691 764 660 787 Weighted-average ordinary shares used in per share calculations - diluted 56,236 57,438 56,297 57,647 Net income per ordinary share: Basic $ 2.67 $ 1.80 $ 1.89 $ 7.90 Diluted $ 2.64 $ 1.78 $ 1.87 $ 7.80 Potentially dilutive ordinary shares from our employee equity incentive and purchase plans and the Exchangeable Senior Notes are determined by applying the treasury stock method to the assumed exercise of share options, the assumed vesting of outstanding restricted stock units, or RSUs, the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP, and the assumed issuance of ordinary shares upon exchange of the Exchangeable Senior Notes. The potential issue of ordinary shares issuable upon exchange of the Exchangeable Senior Notes had no effect on diluted net income per ordinary share because the average price of our ordinary shares for the three and nine months ended September 30, 2020 and 2019 did not exceed the effective exchange prices per ordinary share of the Exchangeable Senior Notes. The following table represents the weighted-average ordinary shares that were excluded from the calculation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Exchangeable Senior Notes 10,192 5,504 7,390 5,504 Options, RSUs and ESPP 5,023 5,062 5,325 5,084

Revenues

Revenues	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenues	Revenues The following table presents a summary of total revenues (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Xyrem $ 447,809 $ 425,644 $ 1,302,492 $ 1,207,173 Defitelio/defibrotide 50,241 37,604 140,387 125,159 Erwinaze/Erwinase 20,145 34,024 90,560 122,545 Vyxeos 30,825 29,581 90,113 89,886 Zepzelca 36,941 — 36,941 — Sunosi 9,116 987 19,618 987 Other 1,872 4,481 5,246 13,325 Product sales, net 596,949 532,321 1,685,357 1,559,075 Royalties and contract revenues 3,939 5,381 12,693 20,946 Total revenues $ 600,888 $ 537,702 $ 1,698,050 $ 1,580,021 The following table presents a summary of total revenues attributed to geographic sources (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 United States $ 548,410 $ 492,366 $ 1,542,990 $ 1,436,160 Europe 45,778 35,037 125,229 106,956 All other 6,700 10,299 29,831 36,905 Total revenues $ 600,888 $ 537,702 $ 1,698,050 $ 1,580,021 The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: Three Months Ended Nine Months Ended 2020 2019 2020 2019 ESSDS 74 % 79 % 77 % 76 % McKesson 10 % 12 % 11 % 14 % Financing and payment Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 45 days. Contract Liabilities - Deferred Revenue The deferred revenue balance as of September 30, 2020 primarily related to deferred upfront fees received from Nippon Shinyaku Co., Ltd., or Nippon Shinyaku, in connection with two license, development and commercialization agreements granting Nippon Shinyaku exclusive rights to develop and commercialize each of Defitelio and Vyxeos in Japan. We recognized contract revenues of $1.2 million and $3.5 million during the three and nine months ended September 30, 2020, respectively, relating to these upfront payments. The deferred revenue balances are being recognized over an average of four years representing the period over which we expect to perform our research and developments obligations under each agreement. The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the nine months ended September 30, 2020 (in thousands): Contract Liabilities Balance as of December 31, 2019 $ 9,581 Amount recognized within royalties and contract revenues (3,540) Balance as of September 30, 2020 $ 6,041

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Selling, general and administrative $ 20,974 $ 20,302 $ 62,590 $ 61,357 Research and development 7,463 6,498 21,511 17,917 Cost of product sales 1,919 1,985 5,513 5,352 Total share-based compensation expense, pre-tax 30,356 28,785 89,614 84,626 Income tax benefit from share-based compensation expense (3,436) (4,106) (10,106) (12,246) Total share-based compensation expense, net of tax $ 26,920 $ 24,679 $ 79,508 $ 72,380 Share Options The table below shows the number of shares underlying options granted to purchase our ordinary shares, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted: Three Months Ended Nine Months Ended 2020 2019 2020 2019 Shares underlying options granted (in thousands) 159 198 803 1,597 Grant date fair value $ 37.75 $ 40.62 $ 34.43 $ 42.32 Black-Scholes option pricing model assumption information: Volatility 36 % 33 % 33 % 32 % Expected term (years) 4.6 4.5 4.6 4.5 Range of risk-free rates 0.2-0.3% 1.5-1.7% 0.2-1.6% 1.5-2.5% Expected dividend yield — % — % — % — % Restricted Stock Units The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted: Three Months Ended Nine Months Ended 2020 2019 2020 2019 RSUs granted (in thousands) 160 80 1,248 642 Grant date fair value $ 123.79 $ 135.90 $ 114.80 $ 138.50 The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares on that date. The fair value of RSUs is expensed ratably over the vesting period, generally over four years.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Our income tax provision was $19.3 million in the three months ended September 30, 2020, compared to $10.9 million for the same period in 2019. Our income tax provision was $22.8 million in the nine months ended September 30, 2020 compared to an income tax benefit of $38.6 million for the same period in 2019. The effective tax rate was 11.5% in the three months ended September 30, 2020 compared to 9.5% for the same period in 2019. The increase in the effective tax rate for the three months ended September 30, 2020 compared to the same period in 2019 was primarily due to the release in 2019 of reserves related to unrecognized tax benefits upon expiration of a statute of limitations, partially offset by the impact of tax credits originating in 2020. The effective tax rate was 17.5% in the nine months ended September 30, 2020, compared to (9.3)% for the same period in 2019. The income tax benefit for the nine months ended September 30, 2019 included a discrete tax benefit of $112.3 million resulting from an intra-entity intellectual property asset transfer. The tax benefit, which represents a deferred future benefit, was recorded as a deferred tax asset. The increase in the effective tax rate for the nine months ended September 30, 2020 compared to the same period in 2019 was primarily due to the impact of the intra-entity intellectual property asset transfer. Excluding this effect, the decrease in the effective tax rate for the nine months ended September 30, 2020 compared to the same period in 2019 was primarily due to the impact of the defibrotide acquired IPR&D asset impairment charge, originating tax credits and the impact of the acquired IPR&D expense related to the original PharmaMar transaction, partially offset by the impact of the disallowance of certain interest deductions and a provision for a proposed settlement reached with the French tax authorities. The effective tax rate for the three months ended September 30, 2020 was lower than the Irish statutory rate of 12.5% primarily due to the impact of originating tax credits. The effective tax rate for the nine months ended September 30, 2020 was higher than the Irish statutory rate of 12.5% primarily due to the impact of the disallowance of certain interest deductions and a provision for a proposed settlement reached with the French tax authorities, partially offset by the defibrotide acquired IPR&D asset impairment charge, originating tax credits and the impact of the acquired IPR&D expense related to the original PharmaMar transaction. We do not provide for Irish income taxes on undistributed earnings of our foreign operations that are intended to be indefinitely reinvested in our foreign subsidiaries. Our net deferred tax asset is comprised primarily of U.S. federal and state tax credits, U.S. federal and state and foreign net operating loss carryforwards and other temporary differences, and is net of deferred tax liabilities related to acquired intangible assets. We maintain a valuation allowance against certain foreign and U.S. deferred tax assets. Each reporting period, we evaluate the need for a valuation allowance on our deferred tax assets by jurisdiction and adjust our estimates as more information becomes available.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event Asset Acquisition and Exclusive License Agreement In October 2020, we entered into an asset purchase and exclusive license agreement with SpringWorks Therapeutics, Inc., or SpringWorks, under which we acquired SpringWorks’ fatty acid amide hydrolase, or FAAH, inhibitor program. Under the terms of the agreement, SpringWorks has assigned or exclusively licensed all assets relating to its FAAH inhibitor program to us, including assignment of SpringWorks’ proprietary FAAH inhibitor PF-04457845, or PF-'845, and its license agreement with Pfizer, Inc., or Pfizer, under which Pfizer exclusively licensed PF-'845 to SpringWorks in 2017. We will initially focus on developing PF-'845 for the potential treatment of post-traumatic stress disorder and associated symptoms. In addition to assuming all milestone and royalty obligations owed by SpringWorks to Pfizer, we made an upfront payment of $35.0 million to SpringWorks, and may make potential milestone payments to SpringWorks of up to $375.0 million upon the achievement of certain clinical, regulatory and commercial milestones, and pay incremental tiered royalties to SpringWorks on future net sales of PF-'845 in the mid- to high-single digit percentages.

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies - (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared following the requirements of the U.S. Securities and Exchange Commission for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or U.S. GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10‑Q should be read in conjunction with our annual consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020, for any other interim period or for any future period. Our significant accounting policies have not changed substantially from those previously described in our Annual Report on Form 10-K for the year ended December 31, 2019. These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries, and intercompany transactions and balances have been eliminated. Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the identification, development and commercialization of meaningful pharmaceutical products that address unmet medical needs.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.
Adoption of New Accounting Standards and Recent Accounting Pronouncements	Adoption of New Accounting Standards In August 2018, the Financial Accounting Standards Board, or FASB, issued ASU No. 2018-15, “Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. We adopted this standard on January 1, 2020 and adoption did not have a material impact on our consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” which simplifies the accounting for goodwill impairment by eliminating Step 2 of the goodwill impairment test. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. We adopted this standard on January 1, 2020 and adoption did not have a material impact on our consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. We adopted this standard on January 1, 2020 and adoption did not have a material impact on our consolidated financial statements. In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (ASC 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” which contains optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform. ASC 848 allows for different elections to be made at different points in time, and the timing of those elections will be documented as applicable. For the avoidance of doubt, we intend to reassess the elections of optional expedients and exceptions included within ASC 848 related to our hedging activities and will document the election of these items on a quarterly basis. ASC 848 is effective for us as of January 1, 2020 and will no longer be available to apply after December 31, 2022. In June 2020, we elected the expedient in ASC 848-50-25-2, which allows us to assume that our hedged interest payments will probably occur regardless of any expected modification in their terms related to reference rate reform. Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes", which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December 15, 2020 with early adoption permitted. The new guidance is not expected to have a material impact on our results of operations and financial position. In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions that are required for contracts to qualify for equity classification and eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. This new standard will be effective for us for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than the fiscal year beginning after December 15, 2020. We may elect to apply the amendments on a retrospective or modified retrospective basis. We are currently evaluating the timing, method of adoption and overall impact of this standard on our consolidated financial statements.
Significant Risks and Uncertainties	Significant Risks and Uncertainties With the global impact of the COVID-19 pandemic, we have developed a comprehensive response strategy including establishing cross-functional response teams and implementing business continuity plans to manage the impact of the COVID-19 pandemic on our employees, patients and our business. Since the second quarter of 2020, we have been experiencing financial and other impacts of the pandemic, and given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, we expect that our business, financial condition, results of operations and growth prospects will continue to be adversely affected in future quarters. With respect to our commercialization activities, the evolving effects of the COVID-19 pandemic continue to have a negative impact on demand, new patient starts and treatments for our products, primarily due to the inherent limitations of telemedicine and a reprioritization of healthcare resources toward COVID-19. The extent of the impact on our ability to generate sales of and revenues from our approved products, execute on new product launches, our clinical development and regulatory efforts, our corporate development objectives and the value of and market for our ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration and severity of the pandemic, governmental “stay-at-home” orders and travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Ireland and other countries, and the effectiveness of actions taken globally to contain and treat the disease. Our financial results are significantly influenced by sales of Xyrem. Our future plans assume that our newly launched oxybate product Xywav, with 92% lower sodium compared to Xyrem, absence of a sodium warning and dosing titration option, will become the treatment of choice for patients who can benefit from oxybate treatment, current Xyrem patients, and patients who previously were not prescribed Xyrem, including those patients for whom sodium content is a concern. While we expect that our business will continue to be substantially dependent on oxybate product sales from both Xyrem and Xywav, there is no guarantee that we can maintain oxybate sales at or near historical levels, or that oxybate sales will continue to grow. Our ability to maintain or increase oxybate sales is subject to a number of risks and uncertainties including, without limitation, those related to the introduction of authorized generic and generic versions of sodium oxybate and/or new products for treatment of cataplexy and/or EDS in narcolepsy in the U.S. market, the current and potential impacts of the ongoing COVID-19 pandemic, including the current and expected future negative impact on demand for our products and the uncertainty with respect to our ability to meet commercial demand in the future, increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including our ability to obtain and maintain adequate coverage and reimbursement for Xywav, challenges to our intellectual property around Xyrem and Xywav, and continued acceptance of Xyrem by physicians and patients and acceptance of Xywav by payors, physicians and patients. In addition to risks related specifically to Xyrem and Xywav, we are subject to other challenges and risks related to successfully commercializing a portfolio of oncology products and other neuroscience products, including Sunosi, Defitelio, Erwinaze, Vyxeos and Zepzelca, and other risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of our late-stage product candidates; effectively commercializing our recently approved products such as Sunosi, Zepzelca and Xywav; obtaining and maintaining adequate coverage and reimbursement for our products; increasing scrutiny of pharmaceutical product pricing and resulting changes in healthcare laws and policy; market acceptance; delays or problems in the supply of our products, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations. In addition, to the extent the COVID-19 pandemic continues to adversely affect our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.
Concentrations of Risk	Concentrations of Risk Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet. We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of September 30, 2020, we had foreign exchange forward contracts with notional amounts totaling $300.5 million. As of September 30, 2020, the outstanding foreign exchange forward contracts had a net liability fair value of $0.1 million. As of September 30, 2020, we had interest rate swap contracts with notional amounts totaling $300.0 million. These outstanding interest rate swap contracts had a net liability fair value of $4.1 million as of September 30, 2020. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant. We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and as of September 30, 2020 and December 31, 2019, allowances on receivables were not material. As of September 30, 2020, two customers accounted for 81% of gross accounts receivable, Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for 73% of gross accounts receivable, and McKesson Corporation and affiliates, or McKesson, which accounted for 8% of gross accounts receivable. As of December 31, 2019, two customers accounted for 89% of gross accounts receivable, ESSDS, which accounted for 77% of gross accounts receivable, and McKesson, which accounted for 12% of gross accounts receivable. We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to Xyrem, the API is manufactured for us by a single source supplier and the finished product is manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based Xyrem supplier.

Cash and Available-for-Sale S_2

Cash and Available-for-Sale Securities - (Tables)	9 Months Ended
	Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Schedule of Cash and Cash Equivalents and Investments	Cash, cash equivalents and investments consisted of the following (in thousands): September 30, 2020 Amortized Gross Gross Estimated Cash and Investments Cash $ 406,338 $ — $ — $ 406,338 $ 406,338 $ — Time deposits 1,255,000 — — 1,255,000 80,000 1,175,000 Money market funds 255,604 — — 255,604 255,604 — Totals $ 1,916,942 $ — $ — $ 1,916,942 $ 741,942 $ 1,175,000 December 31, 2019 Amortized Gross Gross Estimated Cash and Investments Cash $ 333,172 $ — $ — $ 333,172 $ 333,172 $ — Time deposits 460,000 — — 460,000 20,000 440,000 Money market funds 284,172 — — 284,172 284,172 — Totals $ 1,077,344 $ — $ — $ 1,077,344 $ 637,344 $ 440,000

Fair Value Measurement - (Table

Fair Value Measurement - (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table summarizes, by major security type, our available-for-sale securities and derivative contracts as of September 30, 2020 and December 31, 2019 that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands): September 30, 2020 December 31, 2019 Quoted Significant Total Quoted Significant Total Assets: Available-for-sale securities: Time deposits $ — $ 1,255,000 $ 1,255,000 $ — $ 460,000 $ 460,000 Money market funds 255,604 — 255,604 284,172 — 284,172 Foreign exchange forward contracts — 4,079 4,079 — 2,508 2,508 Totals $ 255,604 $ 1,259,079 $ 1,514,683 $ 284,172 $ 462,508 $ 746,680 Liabilities: Interest rate contracts $ — $ 4,143 $ 4,143 $ — $ 1,515 $ 1,515 Foreign exchange forward contracts — 4,221 4,221 — 182 182 Totals $ — $ 8,364 $ 8,364 $ — $ 1,697 $ 1,697

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities - (Tables)	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Gains (Losses) on Derivative Instruments	The impact on accumulated other comprehensive loss and earnings from derivative instruments that qualified as cash flow hedges for the three and nine months ended September 30, 2020 and 2019 was as follows (in thousands): Three Months Ended Nine Months Ended Interest Rate Contracts: 2020 2019 2020 2019 Gain (loss) recognized in accumulated other comprehensive loss, net of tax $ 9 $ (322) $ (4,515) $ (4,361) Loss (gain) reclassified from accumulated other comprehensive loss to interest expense, net of tax 1,160 (236) 2,228 (1,019)
Schedule of Foreign Exchange Gain (Loss) of Outstanding Derivatives	The foreign exchange loss in our condensed consolidated statements of income included the following gains and losses associated with foreign exchange contracts not designated as hedging instruments (in thousands): Three Months Ended Nine Months Ended Foreign Exchange Forward Contracts: 2020 2019 2020 2019 Gain (loss) recognized in foreign exchange loss $ 9,549 $ (7,430) $ 6,943 $ (10,718)
Schedule of the Fair Value of Outstanding Derivatives	The following tables summarize the fair value of outstanding derivatives (in thousands): September 30, 2020 Asset Derivatives Liability Derivatives Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments: Interest rate contracts Other current assets $ — Accrued liabilities $ 4,143 Derivatives not designated as hedging instruments: Foreign exchange forward contracts Other current assets 4,079 Accrued liabilities 4,221 Total fair value of derivative instruments $ 4,079 $ 8,364 December 31, 2019 Asset Derivatives Liability Derivatives Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments: Interest rate contracts Other current assets $ — Accrued liabilities $ 855 Other non-current liabilities 660 Derivatives not designated as hedging instruments: Foreign exchange forward contracts Other current assets 2,508 Accrued liabilities 182 Total fair value of derivative instruments $ 2,508 $ 1,697
Schedule of Offsetting Assets	The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our interest rate contracts and foreign exchange forward contracts subject to such provisions (in thousands): September 30, 2020 Gross Amounts of Recognized Assets/ Liabilities Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Gross Amounts Not Offset in the Consolidated Balance Sheet Description Derivative Financial Instruments Cash Collateral Received (Pledged) Net Amount Derivative assets $ 4,079 $ — $ 4,079 $ (2,255) $ — $ 1,824 Derivative liabilities (8,364) — (8,364) 2,255 — (6,109) December 31, 2019 Gross Amounts of Recognized Assets/ Liabilities Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Gross Amounts Not Offset in the Consolidated Balance Sheet Description Derivative Financial Instruments Cash Collateral Received (Pledged) Net Amount Derivative assets $ 2,508 $ — $ 2,508 $ (596) $ — $ 1,912 Derivative liabilities (1,697) — (1,697) 596 — (1,101)
Schedule of Offsetting Liabilities	The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our interest rate contracts and foreign exchange forward contracts subject to such provisions (in thousands): September 30, 2020 Gross Amounts of Recognized Assets/ Liabilities Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Gross Amounts Not Offset in the Consolidated Balance Sheet Description Derivative Financial Instruments Cash Collateral Received (Pledged) Net Amount Derivative assets $ 4,079 $ — $ 4,079 $ (2,255) $ — $ 1,824 Derivative liabilities (8,364) — (8,364) 2,255 — (6,109) December 31, 2019 Gross Amounts of Recognized Assets/ Liabilities Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Gross Amounts Not Offset in the Consolidated Balance Sheet Description Derivative Financial Instruments Cash Collateral Received (Pledged) Net Amount Derivative assets $ 2,508 $ — $ 2,508 $ (596) $ — $ 1,912 Derivative liabilities (1,697) — (1,697) 596 — (1,101)

Inventories - (Tables)

Inventories - (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Components of Inventories	Inventories consisted of the following (in thousands): September 30, December 31, Raw materials $ 17,338 $ 13,595 Work in process 46,278 36,658 Finished goods 27,788 28,355 Total inventories $ 91,404 $ 78,608

Goodwill and Intangible Assets

Goodwill and Intangible Assets - (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Gross Carrying Amount of Goodwill	The gross carrying amount of goodwill was as follows (in thousands): Balance at December 31, 2019 $ 920,018 Foreign exchange 17,081 Balance at September 30, 2020 $ 937,099
Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets	The gross carrying amounts and net book values of our intangible assets were as follows (in thousands): September 30, 2020 December 31, 2019 Remaining Gross Accumulated Net Book Gross Accumulated Net Book Acquired developed technologies 12.7 $ 3,324,806 $ (1,083,699) $ 2,241,107 $ 3,166,485 $ (864,834) $ 2,301,651 Manufacturing contracts — 12,533 (12,533) — 12,025 (12,025) — Trademarks — 2,903 (2,903) — 2,890 (2,890) — Priority review voucher — — — — 111,101 (111,101) — Total finite-lived intangible assets 3,340,242 (1,099,135) 2,241,107 3,292,501 (990,850) 2,301,651 Acquired IPR&D assets — — — 139,326 — 139,326 Total intangible assets $ 3,340,242 $ (1,099,135) $ 2,241,107 $ 3,431,827 $ (990,850) $ 2,440,977
Schedule of Estimated Future Amortization Costs	Based on finite-lived intangible assets recorded as of September 30, 2020, and assuming the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands): Year Ending December 31, Estimated 2020 (remainder) $ 66,819 2021 219,309 2022 172,424 2023 172,424 2024 172,424 Thereafter 1,437,707 Total $ 2,241,107

Certain Balance Sheet Items - (

Certain Balance Sheet Items - (Tables)	9 Months Ended
	Sep. 30, 2020
Certain Balance Sheet Items [Abstract]
Schedule of Property and Equipment	Property, plant and equipment consisted of the following (in thousands): September 30, December 31, Leasehold improvements $ 53,670 $ 52,294 Land and buildings 47,385 47,053 Manufacturing equipment and machinery 32,077 28,860 Computer software 22,868 25,680 Computer equipment 17,850 16,577 Furniture and fixtures 11,447 11,152 Construction-in-progress 6,072 5,147 Subtotal 191,369 186,763 Less accumulated depreciation and amortization (63,165) (55,257) Property, plant and equipment, net $ 128,204 $ 131,506
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands): September 30, December 31, Rebates and other sales deductions $ 113,062 $ 96,860 Employee compensation and benefits 76,890 80,531 Sales returns reserve 13,574 3,462 Current portion of operating lease liabilities 13,078 12,728 Royalties 10,186 6,931 Inventory-related accruals 9,318 7,816 Consulting and professional services 8,430 7,665 Derivative instrument liabilities 8,364 1,037 Accrued interest 7,762 7,540 Clinical trial accruals 7,614 3,141 Selling and marketing accruals 7,721 10,946 Accrued collaboration expenses 730 2,494 Accrued construction-in-progress 474 3,015 Other 24,868 25,520 Total accrued liabilities $ 302,071 $ 269,686

Debt - (Tables)

Debt - (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The following table summarizes the carrying amount of our indebtedness (in thousands): September 30, December 31, 2021 Notes $ 218,812 $ 575,000 Unamortized discount and debt issuance costs on 2021 Notes (8,207) (38,865) 2021 Notes, net 210,605 536,135 2024 Notes 575,000 575,000 Unamortized discount and debt issuance costs on 2024 Notes (101,099) (117,859) 2024 Notes, net 473,901 457,141 2026 Notes 1,000,000 — Unamortized discount and debt issuance costs on 2026 Notes (186,595) — 2026 Notes, net 813,405 — Term loan 589,773 613,981 Total debt 2,087,684 1,607,257 Less current portion 243,999 33,387 Total long-term debt $ 1,843,685 $ 1,573,870
Schedule of Maturities of Long-term Debt	Scheduled maturities with respect to our long-term debt principal balances outstanding as of September 30, 2020 were as follows (in thousands): Year Ending December 31, Scheduled Long-Term Debt Maturities 2020 (remainder) $ 8,347 2021 252,198 2022 33,387 2023 517,494 2024 575,000 Thereafter 1,000,000 Total $ 2,386,426

Leases - (Tables)

Leases - (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Schedule of Lease Cost and Supplemental Cash Flow Information	The components of the lease expense for the three and nine months ended September 30, 2020 and 2019 were as follows (in thousands): Three Months Ended Nine Months Ended Lease Cost 2020 2019 2020 2019 Operating lease cost $ 5,501 $ 5,746 $ 16,201 $ 17,672 Short-term lease cost 942 396 2,702 1,616 Variable lease cost 1 — 2 4 Sublease income — (158) (224) (478) Net lease cost $ 6,444 $ 5,984 $ 18,681 $ 18,814 Lease Term and Discount Rate September 30, December 31, Weighted-average remaining lease term - operating leases (years) 9.1 9.7 Weighted-average discount rate - operating leases 5.3 % 5.3 % Supplemental cash flow information related to operating leases was as follows (in thousands): Nine Months Ended 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 16,915 $ 11,758 Non-cash operating activities: Right-of-use assets obtained in exchange for new operating lease liabilities (1) $ 1,034 $ 153,048 _____________________________
Schedule of Lease Supplemental Balance Sheet Information	Supplemental balance sheet information related to operating leases was as follows (in thousands): Leases Classification September 30, December 31, Assets Operating lease assets Operating lease assets $ 130,717 $ 139,385 Liabilities Current Operating lease liabilities Accrued liabilities 13,078 12,728 Non-current Operating lease liabilities Operating lease liabilities, less current portion 141,925 151,226 Total operating lease liabilities $ 155,003 $ 163,954
Schedule of Operating Lease Liability Maturities	Maturities of operating lease liabilities were as follows (in thousands): Year Ending December 31, Operating leases 2020 (remainder) $ 4,812 2021 21,618 2022 21,619 2023 21,778 2024 23,992 Thereafter 104,794 Total lease payments 198,613 Less imputed interest (43,610) Present value of lease liabilities $ 155,003

Shareholders' Equity - (Tables)

Shareholders' Equity - (Tables)	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss as of September 30, 2020 and December 31, 2019 were as follows (in thousands): Net Unrealized Foreign Total Balance at December 31, 2019 $ (1,325) $ (222,068) $ (223,393) Other comprehensive income (loss) before reclassifications (4,515) 37,879 33,364 Amounts reclassified from accumulated other comprehensive loss 2,228 — 2,228 Other comprehensive income (loss), net (2,287) 37,879 35,592 Balance at September 30, 2020 $ (3,612) $ (184,189) $ (187,801)

Net Income per Ordinary Share -

Net Income per Ordinary Share - (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Income per Ordinary Share Computation	Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Numerator: Net income $ 148,234 $ 102,276 $ 105,202 $ 449,375 Denominator: Weighted-average ordinary shares used in per share calculations - basic 55,545 56,674 55,637 56,860 Dilutive effect of employee equity incentive and purchase plans 691 764 660 787 Weighted-average ordinary shares used in per share calculations - diluted 56,236 57,438 56,297 57,647 Net income per ordinary share: Basic $ 2.67 $ 1.80 $ 1.89 $ 7.90 Diluted $ 2.64 $ 1.78 $ 1.87 $ 7.80
Schedule of Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share	The following table represents the weighted-average ordinary shares that were excluded from the calculation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Exchangeable Senior Notes 10,192 5,504 7,390 5,504 Options, RSUs and ESPP 5,023 5,062 5,325 5,084

Revenues - (Tables)

Revenues - (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Summary of Disaggregation of Revenue	The following table presents a summary of total revenues (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Xyrem $ 447,809 $ 425,644 $ 1,302,492 $ 1,207,173 Defitelio/defibrotide 50,241 37,604 140,387 125,159 Erwinaze/Erwinase 20,145 34,024 90,560 122,545 Vyxeos 30,825 29,581 90,113 89,886 Zepzelca 36,941 — 36,941 — Sunosi 9,116 987 19,618 987 Other 1,872 4,481 5,246 13,325 Product sales, net 596,949 532,321 1,685,357 1,559,075 Royalties and contract revenues 3,939 5,381 12,693 20,946 Total revenues $ 600,888 $ 537,702 $ 1,698,050 $ 1,580,021 The following table presents a summary of total revenues attributed to geographic sources (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 United States $ 548,410 $ 492,366 $ 1,542,990 $ 1,436,160 Europe 45,778 35,037 125,229 106,956 All other 6,700 10,299 29,831 36,905 Total revenues $ 600,888 $ 537,702 $ 1,698,050 $ 1,580,021
Summary of Revenues from Customers Representing More Than 10% of Total Revenues	The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: Three Months Ended Nine Months Ended 2020 2019 2020 2019 ESSDS 74 % 79 % 77 % 76 % McKesson 10 % 12 % 11 % 14 %
Summary of a Reconciliation in Contract Liabilities from Contracts with Customer	The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the nine months ended September 30, 2020 (in thousands): Contract Liabilities Balance as of December 31, 2019 $ 9,581 Amount recognized within royalties and contract revenues (3,540) Balance as of September 30, 2020 $ 6,041

Share-Based Compensation - (Tab

Share-Based Compensation - (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Share-Based Compensation Expense Related to Share Options, RSUs and Grants Under ESPP	Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Selling, general and administrative $ 20,974 $ 20,302 $ 62,590 $ 61,357 Research and development 7,463 6,498 21,511 17,917 Cost of product sales 1,919 1,985 5,513 5,352 Total share-based compensation expense, pre-tax 30,356 28,785 89,614 84,626 Income tax benefit from share-based compensation expense (3,436) (4,106) (10,106) (12,246) Total share-based compensation expense, net of tax $ 26,920 $ 24,679 $ 79,508 $ 72,380
Schedule of Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model which was Used to Estimate Grant Date Fair Value per Share	The table below shows the number of shares underlying options granted to purchase our ordinary shares, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted: Three Months Ended Nine Months Ended 2020 2019 2020 2019 Shares underlying options granted (in thousands) 159 198 803 1,597 Grant date fair value $ 37.75 $ 40.62 $ 34.43 $ 42.32 Black-Scholes option pricing model assumption information: Volatility 36 % 33 % 33 % 32 % Expected term (years) 4.6 4.5 4.6 4.5 Range of risk-free rates 0.2-0.3% 1.5-1.7% 0.2-1.6% 1.5-2.5% Expected dividend yield — % — % — % — %
Schedule of Restricted Stock Unit activity	The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted: Three Months Ended Nine Months Ended 2020 2019 2020 2019 RSUs granted (in thousands) 160 80 1,248 642 Grant date fair value $ 123.79 $ 135.90 $ 114.80 $ 138.50

The Company and Summary of Si_3

The Company and Summary of Significant Accounting Policies - Basis of Presentation Narrative (Details)	9 Months Ended
	Sep. 30, 2020Segment
Accounting Policies [Abstract]
Number of operating business segments	1

The Company and Summary of Si_4

The Company and Summary of Significant Accounting Policies - Concentrations of Risk Narrative (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Customer concentration risk | Gross accounts receivable
Concentration Risk [Line Items]
Percentage of gross accounts receivable (as a percent)	81.00%	89.00%
Customer concentration risk | Gross accounts receivable | Express Scripts
Concentration Risk [Line Items]
Percentage of gross accounts receivable (as a percent)	73.00%	77.00%
Customer concentration risk | Gross accounts receivable | McKesson
Concentration Risk [Line Items]
Percentage of gross accounts receivable (as a percent)	8.00%	12.00%
Foreign exchange forward contracts | Derivatives not designated as hedging instruments
Concentration Risk [Line Items]
Notional amount	$ 300,500,000	$ 180,900,000
Net liability fair value	100,000
Interest rate contracts | Derivatives designated as hedging instruments
Concentration Risk [Line Items]
Notional amount	300,000,000	$ 300,000,000
Net liability fair value	$ 4,100,000

License Agreement - Narrative (

License Agreement - Narrative (Details) - USD ($) $ in Thousands	Dec. 19, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development		$ 10,000	$ 51,775	$ 215,250	$ 109,975
Milestone payment capitalized as intangible asset		$ 3,340,242		3,340,242			$ 3,292,501
Pharma Mar, S.A.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Tiered royalty fees percentage, maximum	30.00%
Upfront Payments | Pharma Mar, S.A.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development				$ 200,000
Accelerated And/Or Full Regulatory Approval Milestone Payments | Pharma Mar, S.A.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones not yet incurred	$ 150,000
Commercial Milestone Payments | Pharma Mar, S.A.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones not yet incurred	$ 550,000
FDA Approval Of Zepzelca
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment capitalized as intangible asset						$ 100,000
FDA Approval Of Zepzelca | Milestone Payment | Pharma Mar, S.A.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment capitalized as intangible asset						$ 100,000

Cash and Available-for-Sale S_3

Cash and Available-for-Sale Securities - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 1,916,942	$ 1,077,344
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	1,916,942	1,077,344
Cash and Cash Equivalents	741,942	637,344
Investments	1,175,000	440,000
Cash
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	406,338	333,172
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	406,338	333,172
Cash and Cash Equivalents	406,338	333,172
Investments	0	0
Time deposits
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	1,255,000	460,000
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	1,255,000	460,000
Cash and Cash Equivalents	80,000	20,000
Investments	1,175,000	440,000
Money market funds
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	255,604	284,172
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	255,604	284,172
Cash and Cash Equivalents	255,604	284,172
Investments	$ 0	$ 0

Cash and Available-for-Sale S_4

Cash and Available-for-Sale Securities - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Interest income from available-for-sale securities	$ 2.1	$ 5.4	$ 9.7	$ 15.2

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Available-for-sale securities:
Available-for-sale securities	$ 1,916,942	$ 1,077,344
Time deposits
Available-for-sale securities:
Available-for-sale securities	1,255,000	460,000
Money market funds
Available-for-sale securities:
Available-for-sale securities	255,604	284,172
Recurring
Available-for-sale securities:
Totals	1,514,683	746,680
Liabilities:
Totals	8,364	1,697
Recurring | Time deposits
Available-for-sale securities:
Available-for-sale securities	1,255,000	460,000
Recurring | Money market funds
Available-for-sale securities:
Available-for-sale securities	255,604	284,172
Recurring | Interest rate contracts
Liabilities:
Derivative liabilities	4,143	1,515
Recurring | Foreign exchange forward contracts
Available-for-sale securities:
Derivative asset	4,079	2,508
Liabilities:
Derivative liabilities	4,221	182
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Available-for-sale securities:
Totals	255,604	284,172
Liabilities:
Totals	0	0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Time deposits
Available-for-sale securities:
Available-for-sale securities	0	0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds
Available-for-sale securities:
Available-for-sale securities	255,604	284,172
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Interest rate contracts
Liabilities:
Derivative liabilities	0	0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign exchange forward contracts
Available-for-sale securities:
Derivative asset	0	0
Liabilities:
Derivative liabilities	0	0
Recurring | Significant Other Observable Inputs (Level 2)
Available-for-sale securities:
Totals	1,259,079	462,508
Liabilities:
Totals	8,364	1,697
Recurring | Significant Other Observable Inputs (Level 2) | Time deposits
Available-for-sale securities:
Available-for-sale securities	1,255,000	460,000
Recurring | Significant Other Observable Inputs (Level 2) | Money market funds
Available-for-sale securities:
Available-for-sale securities	0	0
Recurring | Significant Other Observable Inputs (Level 2) | Interest rate contracts
Liabilities:
Derivative liabilities	4,143	1,515
Recurring | Significant Other Observable Inputs (Level 2) | Foreign exchange forward contracts
Available-for-sale securities:
Derivative asset	4,079	2,508
Liabilities:
Derivative liabilities	$ 4,221	$ 182

Fair Value Measurement - Narrat

Fair Value Measurement - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2020	Jun. 30, 2020	Feb. 15, 2018	Feb. 15, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity securities without readily determinable fair value	$ 4.5
2021 Notes | Convertible Debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate (as a percent)				1.875%
2024 Notes | Convertible Debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate (as a percent)			1.50%
2026 Notes | Convertible Debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate (as a percent)		2.00%
Significant Other Observable Inputs (Level 2) | 2021 Notes | Convertible Debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of exchangeable senior notes	222
Significant Other Observable Inputs (Level 2) | 2024 Notes | Convertible Debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of exchangeable senior notes	584
Significant Other Observable Inputs (Level 2) | 2026 Notes | Convertible Debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of exchangeable senior notes	$ 1,200

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Narrative (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Interest rate contracts
Derivative [Line Items]
Losses recognized in AOCI to be reclassified over the next 12 months	$ 3,600,000
Interest rate contracts | Derivatives designated as hedging instruments
Derivative [Line Items]
Notional amount	$ 300,000,000	$ 300,000,000
Interest rate contracts | Derivatives not designated as hedging instruments
Derivative [Line Items]
Fixed interest rate	1.895%
Foreign exchange forward contracts | Derivatives not designated as hedging instruments
Derivative [Line Items]
Notional amount	$ 300,500,000	$ 180,900,000
Foreign exchange forward contracts | Derivatives not designated as hedging instruments | Maximum
Derivative [Line Items]
Contract term	12 months

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Gains on Derivative Instruments (Details) - Interest rate contracts - Cash Flow Hedges - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in accumulated other comprehensive loss, net of tax	$ 9	$ (322)	$ (4,515)	$ (4,361)
Loss (gain) reclassified from accumulated other comprehensive loss to interest expense, net of tax	$ 1,160	$ (236)	$ 2,228	$ (1,019)

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Foreign Exchange Gain (Loss) Derivative Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivatives not designated as hedging instruments | Foreign exchange forward contracts
Derivative [Line Items]
Gain (loss) recognized in foreign exchange loss	$ 9,549	$ (7,430)	$ 6,943	$ (10,718)

Derivative Instruments and He_6

Derivative Instruments and Hedging Activities - Fair Value of Outstanding Derivatives (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Asset Derivatives	$ 4,079	$ 2,508
Liability Derivatives	8,364	1,697
Derivatives designated as hedging instruments | Interest rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	0	0
Derivatives designated as hedging instruments | Interest rate contracts | Accrued liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives	4,143	855
Derivatives designated as hedging instruments | Interest rate contracts | Other non-current liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives		660
Derivatives not designated as hedging instruments | Foreign exchange forward contracts | Other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	4,079	2,508
Derivatives not designated as hedging instruments | Foreign exchange forward contracts | Accrued liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives	$ 4,221	$ 182

Derivative Instruments and He_7

Derivative Instruments and Hedging Activities - Offsetting Assets and Liabilities (Details) - Pro Forma - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Derivative assets
Gross Amounts of Recognized Assets/ Liabilities	$ 4,079	$ 2,508
Gross Amounts Offset in the Consolidated Balance Sheet	0	0
Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet	4,079	2,508
Gross Amounts Not Offset in the Consolidated Balance Sheet
Derivative Financial Instruments	(2,255)	(596)
Cash Collateral Received (Pledged)	0	0
Net Amount	1,824	1,912
Derivative liabilities
Gross Amounts of Recognized Assets/ Liabilities	(8,364)	(1,697)
Gross Amounts Offset in the Consolidated Balance Sheet	0	0
Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet	(8,364)	(1,697)
Gross Amounts Not Offset in the Consolidated Balance Sheet
Derivative Financial Instruments	2,255	596
Cash Collateral Received (Pledged)	0	0
Net Amount	$ (6,109)	$ (1,101)

Inventories - Components of Inv

Inventories - Components of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 17,338	$ 13,595
Work in process	46,278	36,658
Finished goods	27,788	28,355
Total inventories	$ 91,404	$ 78,608

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill Activity (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Goodwill [Roll Forward]
Goodwill, beginning of period	$ 920,018
Foreign exchange	17,081
Goodwill, end of period	$ 937,099

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Gross Carrying Amounts and Net Book Values of Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Jan. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 3,340,242			$ 3,292,501
Accumulated Amortization	(1,099,135)			(990,850)
Total	2,241,107			2,301,651
Intangible Assets [Line Items]
Gross Carrying Amount - Total Intangible Assets	3,340,242			3,431,827
Net Book Value - Total Intangible Assets	2,241,107			2,440,977
Acquired IPR&D assets
Intangible Assets [Line Items]
In-process research and development	0			139,326
Impairment of intangible assets	$ 136,100
Acquired developed technologies
Finite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	12 years 8 months 12 days
Gross Carrying Amount	$ 3,324,806			3,166,485
Accumulated Amortization	(1,083,699)			(864,834)
Total	$ 2,241,107			2,301,651
Manufacturing contracts
Finite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	0 years
Gross Carrying Amount	$ 12,533			12,025
Accumulated Amortization	(12,533)			(12,025)
Total	$ 0			0
Trademarks
Finite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	0 years
Gross Carrying Amount	$ 2,903			2,890
Accumulated Amortization	(2,903)			(2,890)
Total	$ 0			0
Priority review voucher
Finite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	0 years
Gross Carrying Amount	$ 0			111,101
Accumulated Amortization	0			(111,101)
Total	$ 0			$ 0
FDA Approval Of Zepzelca
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		$ 100,000
European Marketing Authorization Of Sunosi
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount			$ 13,000

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Estimated Future Amortization Costs (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
2020 (remainder)	$ 66,819
2021	219,309
2022	172,424
2023	172,424
2024	172,424
Thereafter	1,437,707
Total	$ 2,241,107	$ 2,301,651

Certain Balance Sheet Items - P

Certain Balance Sheet Items - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 191,369	$ 186,763
Less accumulated depreciation and amortization	(63,165)	(55,257)
Property, plant and equipment, net	128,204	131,506
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	53,670	52,294
Land and buildings
Property, Plant and Equipment [Line Items]
Property and equipment, gross	47,385	47,053
Manufacturing equipment and machinery
Property, Plant and Equipment [Line Items]
Property and equipment, gross	32,077	28,860
Computer software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	22,868	25,680
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	17,850	16,577
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	11,447	11,152
Construction-in-progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 6,072	$ 5,147

Certain Balance Sheet Items - A

Certain Balance Sheet Items - Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Certain Balance Sheet Items [Abstract]
Rebates and other sales deductions	$ 113,062	$ 96,860
Employee compensation and benefits	76,890	80,531
Sales returns reserve	13,574	3,462
Current portion of operating lease liabilities	13,078	12,728
Royalties	10,186	6,931
Inventory-related accruals	9,318	7,816
Consulting and professional services	8,430	7,665
Derivative instrument liabilities	8,364	1,037
Accrued interest	7,762	7,540
Clinical trial accruals	7,614	3,141
Selling and marketing accruals	7,721	10,946
Accrued collaboration expenses	730	2,494
Accrued construction-in-progress	474	3,015
Other	24,868	25,520
Total accrued liabilities	$ 302,071	$ 269,686

Debt - Schedule of Long-term De

Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Long term debt outstanding	$ 2,386,426
Total debt	2,087,684	$ 1,607,257
Less current portion	243,999	33,387
Total long-term debt	1,843,685	1,573,870
Convertible Debt | 2021 Notes
Debt Instrument [Line Items]
Long term debt outstanding	218,812	575,000
Unamortized discount and debt issuance costs	(8,207)	(38,865)
Total debt	210,605	536,135
Convertible Debt | 2024 Notes
Debt Instrument [Line Items]
Long term debt outstanding	575,000	575,000
Unamortized discount and debt issuance costs	(101,099)	(117,859)
Total debt	473,901	457,141
Convertible Debt | 2026 Notes
Debt Instrument [Line Items]
Long term debt outstanding	1,000,000	0
Unamortized discount and debt issuance costs	(186,595)	0
Total debt	813,405	0
Term Loan
Debt Instrument [Line Items]
Total debt	$ 589,773	$ 613,981

Debt - Narrative (Details)

Debt - Narrative (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)d$ / shares	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Feb. 15, 2018	Feb. 15, 2015
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 5,089,000	$ 0
Partial repurchase of Exchangeable Senior Notes, due 2021, equity component	$ 444,000	$ 12,069,000
Long term debt outstanding	2,386,426,000		2,386,426,000
Convertible Debt | 2026 Notes
Debt Instrument [Line Items]
Debt instrument, face amount		$ 1,000,000,000
Interest rate (as a percent)		2.00%
Debt instrument, convertible, threshold percentage of stock price trigger		130.00%
Debt instrument, convertible, threshold trading days | d		20
Debt instrument, convertible, threshold consecutive trading days | d		30
Debt instrument, convertible, number of shares per principal amount basis (in shares)		0.0064182
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares		$ 155.81
Effective interest rate		5.98%
Term		6 years
Debt issuance costs		$ 18,600,000
Long term debt outstanding	1,000,000,000		1,000,000,000		$ 0
Carrying value of the equity component	176,300,000		176,300,000
Convertible Debt | 2021 Notes
Debt Instrument [Line Items]
Debt instrument, amount repurchased	23,300,000	$ 332,900,000	23,300,000
Interest rate (as a percent)							1.875%
Loss on extinguishment of debt	600,000		5,100,000
Partial repurchase of Exchangeable Senior Notes, due 2021, equity component			12,500,000
Long term debt outstanding	218,812,000		218,812,000		575,000,000
Carrying value of the equity component	114,400,000		114,400,000
Convertible Debt | 2024 Notes
Debt Instrument [Line Items]
Interest rate (as a percent)						1.50%
Long term debt outstanding	575,000,000		575,000,000		$ 575,000,000
Carrying value of the equity component	$ 149,800,000		$ 149,800,000
Jazz Investments I Limited
Debt Instrument [Line Items]
Percentage of ownership (as a percent)	100.00%		100.00%

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of Long-term Debt (Details) $ in Thousands	Sep. 30, 2020USD ($)
Debt Disclosure [Abstract]
2020 (remainder)	$ 8,347
2021	252,198
2022	33,387
2023	517,494
2024	575,000
Thereafter	1,000,000
Total	$ 2,386,426

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Operating lease cost	$ 5,501	$ 5,746	$ 16,201	$ 17,672
Short-term lease cost	942	396	2,702	1,616
Variable lease cost	1	0	2	4
Sublease income	0	(158)	(224)	(478)
Net lease cost	$ 6,444	$ 5,984	$ 18,681	$ 18,814

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Assets:
Operating lease assets	$ 130,717	$ 139,385
Liabilities
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:AccruedLiabilitiesCurrent
Current portion of operating lease liabilities	$ 13,078	12,728
Operating lease liabilities, less current portion	141,925	151,226
Total operating lease liabilities	$ 155,003	$ 163,954

Leases - Weighted Average Terms

Leases - Weighted Average Terms and Discount Rates (Details)	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Weighted-average remaining lease term - operating leases (years)	9 years 1 month 6 days	9 years 8 months 12 days
Weighted-average discount rate - operating leases	5.30%	5.30%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflows from operating leases	$ 16,915	$ 11,758
Non-cash operating activities:
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 1,034	$ 153,048

Leases - Maturities of Operatin

Leases - Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
2020 (remainder)	$ 4,812
2021	21,618
2022	21,619
2023	21,778
2024	23,992
Thereafter	104,794
Total lease payments	198,613
Less imputed interest	(43,610)
Present value of lease liabilities	$ 155,003	$ 163,954

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) $ in Millions	Jun. 23, 2020litigation_case	Sep. 30, 2020USD ($)
Loss Contingencies [Line Items]
Noncancelable purchase commitments due within one year | $		$ 75.4
Teamsters and GEHA Lawsuits
Loss Contingencies [Line Items]
Class action lawsuits filed | litigation_case	2

Shareholders' Equity - Share Re

Shareholders' Equity - Share Repurchase Programs (Details) - Ordinary Options - November 2016 Share Repurchase Program $ / shares in Units, shares in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)$ / sharesshares
Stock Activity [Line Items]
Total amount authorized for repurchase of shares under share repurchase program	$ 1,500,000,000	$ 1,500,000,000
Shares repurchased	0	$ 146,500,000
Shares repurchased (in shares) | shares		1.2
Average price of shares repurchased (in dollars per share) | $ / shares		$ 121.98
Remaining amount authorized for repurchase of shares	$ 431,200,000	$ 431,200,000

Shareholders' Equity - Componen

Shareholders' Equity - Component of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ 3,141,805	$ 2,808,500	$ 3,110,981	$ 2,983,434	$ 2,730,447	$ 2,757,422	$ 3,110,981	$ 2,757,422
Other comprehensive income (loss) before reclassifications							33,364
Amounts reclassified from accumulated other comprehensive loss							2,228
Other comprehensive income (loss)	48,308	21,327	(34,043)	(49,006)	10,238	(22,883)	35,592	(61,651)
Ending balance	3,377,201	3,141,805	2,808,500	3,054,405	2,983,434	2,730,447	3,377,201	3,054,405
Net Unrealized Gain (Loss) From Hedging Activities
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			(1,325)				(1,325)
Other comprehensive income (loss) before reclassifications							(4,515)
Amounts reclassified from accumulated other comprehensive loss							2,228
Other comprehensive income (loss)							(2,287)
Ending balance	(3,612)						(3,612)
Foreign Currency Translation Adjustments
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			(222,068)				(222,068)
Other comprehensive income (loss) before reclassifications							37,879
Amounts reclassified from accumulated other comprehensive loss							0
Other comprehensive income (loss)							37,879
Ending balance	(184,189)						(184,189)
Total Accumulated Other Comprehensive Loss
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(236,109)	(257,436)	(223,393)	(210,436)	(220,674)	(197,791)	(223,393)	(197,791)
Other comprehensive income (loss)	48,308	21,327	(34,043)	(49,006)	10,238	(22,883)
Ending balance	$ (187,801)	$ (236,109)	$ (257,436)	$ (259,442)	$ (210,436)	$ (220,674)	$ (187,801)	$ (259,442)

Net Income per Ordinary Share_2

Net Income per Ordinary Share - Basic and Diluted Net Income per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator:
Net income	$ 148,234	$ 114,801	$ (157,833)	$ 102,276	$ 261,898	$ 85,201	$ 105,202	$ 449,375
Denominator:
Weighted-average ordinary shares used in per share calculation - basic (in shares)	55,545			56,674			55,637	56,860
Dilutive effect of employee equity incentive and purchase plans (in shares)	691			764			660	787
Weighted-average ordinary shares used in per share calculation - diluted (in shares)	56,236			57,438			56,297	57,647
Net income per ordinary share:
Basic (in dollars per share)	$ 2.67			$ 1.80			$ 1.89	$ 7.90
Diluted (in dollars per share)	$ 2.64			$ 1.78			$ 1.87	$ 7.80

Net Income per Ordinary Share_3

Net Income per Ordinary Share - Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Exchangeable Senior Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares (in shares)	10,192	5,504	7,390	5,504
Options, RSUs and ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares (in shares)	5,023	5,062	5,325	5,084

Revenues - Summary of Disaggreg

Revenues - Summary of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenues	$ 600,888	$ 537,702	$ 1,698,050	$ 1,580,021
United States
Disaggregation of Revenue [Line Items]
Total revenues	548,410	492,366	1,542,990	1,436,160
Europe
Disaggregation of Revenue [Line Items]
Total revenues	45,778	35,037	125,229	106,956
All other
Disaggregation of Revenue [Line Items]
Total revenues	6,700	10,299	29,831	36,905
Product sales, net
Disaggregation of Revenue [Line Items]
Total revenues	596,949	532,321	1,685,357	1,559,075
Xyrem
Disaggregation of Revenue [Line Items]
Total revenues	447,809	425,644	1,302,492	1,207,173
Defitelio/defibrotide
Disaggregation of Revenue [Line Items]
Total revenues	50,241	37,604	140,387	125,159
Erwinaze/Erwinase
Disaggregation of Revenue [Line Items]
Total revenues	20,145	34,024	90,560	122,545
Vyxeos
Disaggregation of Revenue [Line Items]
Total revenues	30,825	29,581	90,113	89,886
Zepzelca
Disaggregation of Revenue [Line Items]
Total revenues	36,941	0	36,941	0
Sunosi
Disaggregation of Revenue [Line Items]
Total revenues	9,116	987	19,618	987
Other
Disaggregation of Revenue [Line Items]
Total revenues	1,872	4,481	5,246	13,325
Royalties and contract revenues
Disaggregation of Revenue [Line Items]
Total revenues	$ 3,939	$ 5,381	$ 12,693	$ 20,946

Revenues - Summary of the Perce

Revenues - Summary of the Percentage of Total Revenues from Customers (Details) - Total Revenues - Customer concentration risk	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Express Scripts
Concentration Risk [Line Items]
Percentage of total revenues (as a percent)	74.00%	79.00%	77.00%	76.00%
McKesson
Concentration Risk [Line Items]
Percentage of total revenues (as a percent)	10.00%	12.00%	11.00%	14.00%

Revenues - Narrative (Details)

Revenues - Narrative (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020USD ($)agreement	Sep. 30, 2020USD ($)agreement
Financing and Payment [Line Items]
Contract revenue recognized		$ 3,540
Minimum
Financing and Payment [Line Items]
Payment terms, range		30 days
Maximum
Financing and Payment [Line Items]
Payment terms, range		45 days
Nippon Shinyaku
Financing and Payment [Line Items]
Number of license, development and commercialization agreements | agreement	2	2
Contract revenue recognized	$ 1,200	$ 3,500
Revenue, performance obligation, description of timing		The deferred revenue balances are being recognized over an average of four years representing the period over which we expect to perform our research and developments obligations under each agreement.

Revenues - Summary of Contract

Revenues - Summary of Contract Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Change In Contract With Customer, Liability [Roll Forward]
Beginning balance	$ 9,581
Amount recognized within royalties and contract revenues	(3,540)
Ending balance	$ 6,041

Share-Based Compensation - Expe

Share-Based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	$ 30,356	$ 28,785	$ 89,614	$ 84,626
Income tax benefit from share-based compensation expense	(3,436)	(4,106)	(10,106)	(12,246)
Total share-based compensation expense, net of tax	26,920	24,679	79,508	72,380
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	20,974	20,302	62,590	61,357
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	7,463	6,498	21,511	17,917
Cost of product sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	$ 1,919	$ 1,985	$ 5,513	$ 5,352

Share-Based Compensation - Weig

Share-Based Compensation - Weighted-Average Assumptions and Resulting Grant Date Fair Value (Details) - Employee Stock Option - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Schedule of Weighted Average Assumptions for Fair Values of Stock Options[Line Items]
Shares underlying options granted (in shares)	159	198	803	1,597
Weighted-average grant date fair value (in dollars per share)	$ 37.75	$ 40.62	$ 34.43	$ 42.32
Weighted-average volatility (as a percent)	36.00%	33.00%	33.00%	32.00%
Weighted-average expected term	4 years 7 months 6 days	4 years 6 months	4 years 7 months 6 days	4 years 6 months
Range of risk-free rates, minimum (as a percent)	0.20%	1.50%	0.20%	1.50%
Range of risk-free rates, maximum (as a percent)	0.30%	1.70%	1.60%	2.50%
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%	0.00%

Share-Based Compensation - Rest

Share-Based Compensation - Restricted Units (Details) - Restricted Stock Units (RSUs) - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs granted (in shares)	160	80	1,248	642
Grant date fair value (in dollars per share)	$ 123.79	$ 135.90	$ 114.80	$ 138.50

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Unrecognized compensation cost related to unvested stock option and RSUs	$ 152.6
Weighted-average period expected to be recognized	2 years 10 months 24 days
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested stock option and RSUs	$ 66.8
Weighted-average period expected to be recognized	2 years 6 months

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Taxes [Line Items]
Income tax provision (benefit)	$ 19,283	$ 10,903	$ 22,750	$ (38,631)
Effective income tax rate (as a percent)	11.50%	9.50%	17.50%	(9.30%)
Discrete income tax benefit resulting from intra- entity intellectual property asset transfer				$ 112,300
Ireland
Income Taxes [Line Items]
Ireland statutory income tax rate (as a percent)	12.50%		12.50%
France
Income Taxes [Line Items]
Income tax examination, tax, penalties and interest accrued	$ 18,500		$ 18,500
Income tax examination, tax, penalties and interest expense			18,500
Tax Year 2012 and 2013 | France
Income Taxes [Line Items]
Proposed additional tax including interest and penalties			43,800
Tax Year 2015 and 2016 and 2017 | France
Income Taxes [Line Items]
Proposed additional tax including interest and penalties			$ 12,500

Subsequent Event - Narrative (D

Subsequent Event - Narrative (Details) - SpringWorks - Subsequent Event	1 Months Ended
	Oct. 31, 2020USD ($)
Subsequent Event [Line Items]
Upfront payment paid	$ 35,000,000
Clinical, Regulatory And Commercial Milestones
Subsequent Event [Line Items]
Milestones not yet incurred	$ 375,000,000